



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/01, 5/04, 15/82, A01H 1/06, 4/00, 5/00, 5/10	A1	(11) International Publication Number: WO 00/39291 (43) International Publication Date: 6 July 2000 (06.07.00)
(21) International Application Number: PCT/US99/31312 (22) International Filing Date: 30 December 1999 (30.12.99) (30) Priority Data: 60/115,791 31 December 1998 (31.12.98) US (71) Applicants (for all designated States except US): RUTGERS, THE STATE UNIVERSITY [US/US]; Old Queens, Somerset Street, New Brunswick, NJ 08903 (US). THE UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY [US/US]; 335 George Street, Suite 3200, P.O. Box 2688, New Brunswick, NJ 08903-2688 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): TUMER, Nilgun, E. [US/US]; 50 Red Oak Way, Belle Mead, NJ 08502 (US). DINMAN, Jonathan, D. [US/US]; 33 Princess Drive, North Brunswick, NJ 08902 (US). HUDAK, Katalin, A. [CA/US]; 221B Taylor Avenue, East Brunswick, NJ 08816 (US). (74) Agents: FOLEY, Shawn, P. et al.; Lerner, David, Littenberg, Krumholz & Mentlik, LLP, 600 South Avenue West, Westfield, NJ 07090 (US).	(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report.	
(54) Title: VIRUS-RESISTANT TRANSGENIC PLANTS EXPRESSING L3		
(57) Abstract <p>Disclosed are transgenic plants containing an exogenous nucleic acid encoding an L3 protein. The plant exhibits increased resistance to viruses and/or fungi that infect plants. The L3 proteins include wild-type proteins, spontaneously occurring mutants and non-naturally occurring L3 mutants. Also disclosed are methods of reducing the toxicity of single-chain ribosome inhibitory proteins in cells, e.g., yeast, plant and animal cells, by co-administering the L3 protein with the RIP. Further disclosed are non-naturally occurring L3 mutants that (a) substantially fail to bind single-chain RIPs that bind endogenous L3 proteins, (b) are unable to maintain M1 killer virus, (c) promote altered programmed ribosomal frameshift efficiency, (d) exhibit resistance to peptidyltransferase inhibitors, and combinations of any of (a)-(d).</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

VIRUS-RESISTANT TRANSGENIC PLANTS EXPRESSING L3

CROSS-REFERENCE TO RELATED APPLICATIONS

5 This application claims priority 35 U.S.C 119(e) from United States Application No. 60/115,791, filed December 31, 1998, the content of which is incorporated by reference.

GOVERNMENT SUPPORT

10 The development of this invention was supported in part by National Science Foundation Grants MCB96-31308, MCB97-27941 and MCB98-07890. Therefore, the Government may have certain rights in the invention.

TECHNICAL FIELD

15 This invention relates generally to agricultural biotechnology, and more specifically to methods and genetic elements for conferring resistance to fungi and/or viruses in plants.

BACKGROUND ART

20 The subject of plant protection against pathogens remains the area of utmost importance in agriculture. Many commercially valuable agricultural crops are prone to infection by plant viruses and fungi capable of inflicting significant damage to a crop in a given season, and drastically reducing its economic value. The reduction in economic value to the farmer in turn results in a higher cost of goods to ultimate purchasers. Several published studies have been directed to the expression of plant virus capsid proteins in a plant in an effort to confer resistance to viruses. See, e.g. Abel, *et al.*, Science 232:738-743 (1986); Cuozzo, *et al.*, Bio/Technology 6:549-57 (1988); Hemenway, *et al.*, EMBO J. 25 7:1273-80 (1988); Stark, *et al.*, Bio/Technology 7:1257-62 (1989); and Lawson, *et al.*, Bio/Technology 8:127-34 (1990). However, the transgenic plants exhibited resistance only to the homologous virus and related viruses, but not to unrelated viruses. Kawchuk, *et al.*, Mol. Plant-Microbe Interactions 3(5):301-307 (1990), disclose the expression of wild-type potato leafroll virus (PLRV) coat protein gene in potato plants. Even though the infected 30 plants exhibited resistance to PLRV, all of the transgenic plants that were inoculated with PLRV became infected with the virus and thus disadvantageously allowed for the continued transmission of the virus such that high levels of resistance could not be expected. See U.S. Patent 5,304,730.

Fungal pathogens contribute significantly to the most severe pathogen outbreaks in plants. Plants have developed a natural defense system, including morphological modifications in their cell walls, and synthesis of various anti-pathogenic compounds. See, e.g. Boller, *et al.*, Plant Physiol. 74:442-444 (1984); Bowles, Annu. Rev. Biochem. 59:873-907 (1990); Joosten, *et al.*, Plant Physiol. 89:945-951 (1989); Legrand, *et al.*, Proc. Natl. Acad. Sci. USA 84:6750-6754 (1987); and Roby, *et al.*, Plant Cell 2:999-1007 (1990). Several pathogenesis-related (PR) proteins have been shown to have anti-fungal properties and are induced following pathogen infection. These are different forms of hydrolytic enzymes, such as chitinases and β -1,3-glucanases that inhibit fungal growth *in vitro* by destroying fungal cell walls. See, e.g. Boller, *et al.*, *supra*; Grenier, *et al.*, Plant Physiol. 103:1277-1283 (1993); Leah, *et al.*, J. Biol. Chem. 266:1464-1573 (1991); Mauch, *et al.*, Plant Physiol. 87:325-333 (1988); and Sela-Buurlage Buurlage, *et al.*, Plant Physiol. 101:857-863 (1993).

Several attempts have been made to enhance the pathogen resistance of plants via recombinant methodologies using genes encoding pathogenesis-related proteins (such as chitinases and β -1,3-glucanases) with distinct lytic activities against fungal cell walls. See, e.g., Broglie, *et al.*, Science 254:1194-1197 (1991); Vierheilig, *et al.*, Mol. Plant-Microbe Interact. 6:261-264 (1993); and Zhu, *et al.*, Bio/Technology 12:807-812 (1994). Recently, two other classes of genes have been shown to have potential in conferring disease resistance in plants. Wu, *et al.*, Plant Cell 7:1357-1368 (1995), reports that a transgenic potato expressing the *Aspergillus niger* glucose oxidase gene exhibited increased resistance to *Erwinia carotovora* and *Phytophthora infestans*. The hypothesis is that the glucose oxidase-catalyzed oxidation of glucose produces hydrogen peroxide, which when accumulates in plant tissues, leads to the accumulation of active oxygen species, which in turn, triggers production of various anti-pathogen and anti-fungal mechanisms such as phytoalexins (see Apostol, *et al.*, Plant Physiol. 90:109-116 (1989) and Degousee, Plant Physiol. 104:945-952 (1994)), pathogenesis-related proteins (Klessig, *et al.*, Plant Mol. Biol. 26:1439-1458 (1994)), strengthening of the plant cell wall (Brisson, *et al.*, Plant Cell 6:1703-1712 (1994)), induction of systemic acquired resistance by salicylic acid (Chen, *et al.*, Science 162:1883-1886 (1993)), and hypersensitive defense response (Levine, *et al.*, Cell 79:583-593 (1994)).

In addition to the studies on virus resistance in plants, ribosome inactivating proteins (RIPs) have been studied in conjunction with fungal resistance. For example,

Logeman, *et al.*, Bio/Technology 10:305-308 (1992), report that an RIP isolated from barley endosperm provided protection against fungal infection to transgenic tobacco plants. The combination of barley endosperm RIP and barley class-II chitinase has provided synergistic enhancement of resistance to *Rhizoctonia solani* in tobacco, both *in vitro* and *in vivo*. See, e.g., Lea, *et al.*, *supra*; Mauch, *et al.*, *supra*; Zhu, *et al.*, *supra*; and Jach, *et al.*, The Plant Journal 8:97-109 (1995). PAP, however, has not shown antifungal activity *in vitro*. See Chen, *et al.*, Plant Pathol. 40:612-620 (1991), which reports that PAP has no effect on the growth of the fungi *Phytophthora infestans*, *Colletotrichum coccodes*, *fusarium solani*, *fusarium sulphureum*, *Phoma foreata* and *Rhizoctonia solani* *in vitro*.

Lodge, *et al.*, Proc. Natl. Acad. Sci. USA 90:7089-7093 (1993), report the *Agrobacterium tumefaciens*-mediated transformation of tobacco with a cDNA encoding wild-type pokeweed antiviral protein (PAP) and the resistance of the transgenic tobacco plants to unrelated viruses. PAP, a Type I ribosome-inhibiting protein (RIP) found in the cell walls of *Phytolacca americana* (pokeweed), is a single polypeptide chain that catalytically removes a specific adenine residue from a highly conserved stem-loop structure in the 28S rRNA of eukaryotic ribosomes, and interferes with elongation factor-2 binding and blocking cellular protein synthesis. See, e.g., Irvin *et al.*, Pharmac. Ther. 55:279-302 (1992); Endo, *et al.*, Biophys. Res. Comm., 150:1032-1036 (1988); and Hartley, *et al.*, FEBS Lett. 290:65-68 (1991). The observations by Lodge were in sharp contrast to previous studies, *supra*, which reported that transgenic plants expressing a viral gene were resistant to that virus and closely related viruses only. See also Beachy, *et al.*, Ann. Rev. Phytopathol. 28:451-474 (1990); and Golemboski, *et al.*, Proc. Natl. Acad. Sci. USA 87:6311-15 (1990). Lodge also reports, however, that the PAP-expressing tobacco plants (i.e., above 10 ng/mg protein) tended to have a stunted, mottled phenotype, and that other transgenic tobacco plants that accumulated the highest levels of PAP were sterile. RIPs have proven unpredictable in other respects such as target specificity. Unlike PAP which (as demonstrated in Lodge, *supra*), ricin isolated from castor bean seed is 1000 times more active on mammalian ribosomes than plant ribosomes. See, e.g., Harley, *et al.*, Proc. Natl. Acad. Sci. USA 79:5935-5938 (1982). Barley endosperm RIP also shows very little activity against plant ribosomes. See, e.g. Endo, *et al.*, Biochem. Biophys. Acta 994:224-226 (1988) and Taylor, *et al.*, Plant J. 5:827-835 (1984).

U.S. Patents 5,756,322 and 5,880,322 teach PAP mutants that when produced in plants exhibit less toxicity than wild-type PAP and exhibit biological activities

(e.g., resistance to viruses, fungi and other pests) akin to wild-type PAP. It has also been reported that PAP II and PAP II mutants exhibit reduced phytotoxicity compared to wild-type PAP. See Wang, *et al.*, Plant Mol. Biol. 38:957-964 (1998).

Nonetheless, a need remains for a means by which to confer broad spectrum virus and/or fungus resistance to plants without causing cell death or sterility, and which requires a minimum number of transgenes. There is also a need to enhance the anti-viral and anti-fungal properties imparted by PAP while reducing the phytotoxicity associated with PAP.

SUMMARY OF THE INVENTION

L3 is a highly conserved ribosomal protein that participates in the formation of the peptidyltransferase center that in turn allows elongation of the ribosome along the messenger RNA (mRNA). Hampl, *et al.*, J. Biol. Chem. 256:2284-2288 (1981); Noller, J. Bacteriol. 175:5297-5300 (1993). L3 also plays an essential role in the catalysis of peptide bond formation. See, Green, *et al.*, Annu. Rev. Biochem. 66:679-716 (1997). This is an essential step in protein synthesis in yeast, animals and higher plants.

Applicants have discovered that PAP, a protein that imparts resistance to plant pests such as viruses and fungi when expressed in or applied to plants but which is relatively toxic to plants, recognizes its ribosomal substrate by binding to L3. Applicants have also discovered that PAP does not depurinate ribosomes and thus is non-toxic in the presence of certain L3 mutants. Applicants have further discovered that expression of L3 proteins in plants confers resistance to a broad range of viruses and fungi.

Accordingly, a first aspect of the present invention is directed to a transgenic plant having an exogenous nucleic acid containing a sequence encoding an L3 protein. Expression of the L3 nucleic acid sequence results in increased resistance to a broad spectrum of viruses and fungi to the plant. In preferred embodiments, the L3 nucleic acid is obtained or derived from yeast, a higher plant or an animal. It may be homologous or heterologous with respect to the plant in which it is being introduced. In other preferred embodiments, the L3 protein is a spontaneously occurring mutant of L3 or a non-naturally occurring L3 mutant. In other preferred embodiments, the transgenic plant also has a second exogenous nucleic acid containing a sequence encoding a single chain RIP that accesses ribosomes (and depurinates them) by binding an endogenous L3 protein, the expression of which results in increased anti-fungal and/or anti-fungal resistance to the plant. In more preferred embodiments, the RIP is PAP, a PAP mutant, PAP- ν , PAP II or a

PAP II mutant. Preferred transgenic plants include monocots and dicots. Protoplasts and plant cells transformed (stably or transiently) with exogenous nucleic acid(s) are also provided. Seed derived from the transgenic plants are further provided. An advantage of using L3 is that unlike PAP and other RIPs, it is substantially non-toxic to both prokaryotic and eukaryotic cells and whole plants.

Another aspect of the present invention is directed to methods of increasing resistance to viruses and fungi in plants by administering to a plant the L3 proteins of the present invention. In one preferred embodiment, the L3 nucleic acid is introduced into the plant; in another, it is introduced into a protoplast and the whole plant is regenerated therefrom.

Yet another aspect of the present invention is directed to methods for reducing the phytotoxicity associated with the production in plants of anti-viral and/or anti-fungal single-chain RIPs such as PAP, PAP- ν and PAP II proteins. The methods entail co-production of an L3 protein. Without intending to be bound by any particular theory of operation, Applicants believe that expression of exogenous wild type L3 competes with the RIP for binding to the endogenous L3 protein and thus reduces phytotoxicity. It is also believed that the L3 mutants of the present invention do not bind the RIP thus severing the pathway that leads to the phytotoxic effect but still allow for an anti-viral and/or anti-fungal phenotype.

A further aspect of the present invention is directed to nucleic acids that encode various non-naturally occurring L3 mutants. The mutants are characterized by one or more of the following properties, namely: they substantially fail to bind single-chain RIPs that bind endogenous L3 to access ribosomes *in vivo*; they are unable to maintain an M1 killer virus; they alter (e.g. increase or in some cases, decrease) programmed ribosomal frameshift efficiency and they exhibit resistance to peptidyltransferase inhibitors. The L3 mutants *per se* are also provided as well as cells (e.g., prokaryotic cells including bacteria and eucaryotic cells such as yeast) transformed with the nucleic acids, as well as compositions containing the mutant and a carrier.

Other aspects of the present invention pertain to reducing the toxicity of single chain RIPs in cells other than plant cells. The method entails co-administering (e.g., co-expressing) to a cell the RIP and an L3 protein. In preferred embodiments, the cell is a bacterial cell such as *E. coli* transformed with a nucleic acid encoding wild type PAP or a

PAP mutant and another nucleic acid encoding the L3 protein. In more preferred embodiments, the L3 protein is a non-naturally occurring mutant as described herein.

BEST MODE OF CARRYING OUT INVENTION

5 Transgenic plants expressing L3 or an L3 mutant exhibit broad spectrum resistance to viruses and fungi. L3 nucleic acids useful in the present invention may be obtained from a variety of natural sources including yeast, higher plants and animals. By the term "exogenous" it is meant in addition to the native genome of the plant. By the term "homologous" it is meant within the same species of organism (e.g., introducing a tomato
10 gene encoding L3 into a tomato). Thus, the present invention embraces transgenic plants producing multiple copies of its own endogenous L3 gene. By "heterologous" it is meant that the L3 gene is derived or obtained from a different species of organism from the plant (e.g., an L3 nucleic acid derived from yeast or another higher plant species). Thus, "exogenous" embraces homologous and heterologous L3 nucleic acids. The nucleotide
15 sequence and corresponding amino acid sequence of the yeast wild-type L3 protein (known as rpl3) are set forth below.

ATGTCTCACAGAAAGTACGAAGCACCGTCACGGTCATTTAGGTTTCTTGCCA
AGAAAG 1 -----+-----+-----+-----+-----+-----+ 60

20 TACAGAGTGTCTTTCATGCTTCGTGGTGCAGTGCCAGTAAATCCAAAGAACGGT
TCTTTC

a M S H R K Y E A P R H G H L G F L P R K -

25 AGAGCTGCCTCCATCAGAGCTAGAGTTAAGGCTTTTCCAAAGGATGACAGATCC
AAGCCA

61 -----+-----+-----+-----+-----+-----+ 120

30 TCTCGACGGAGGTAGTCTCGATCTCAATTCCGAAAAGGTTTCCTACTGTCTAGG
TTCGGT

a R A A S I R A R V K A F P K D D R S K P -

35 GTTGCTCTAACTTCCTTCTTGGGTTACAAGGCTGGTATGACCACCATTGTCAGAG
ATTG

121 -----+-----+-----+-----+-----+-----+ 180

40 CAACGAGATTGAAGGAAGAACCCAATGTTCCGACCATACTGGTGGTAACAGTC
TCTAAAC

a V A L T S F L G Y K A G M T T I V R D L -

5 GACAGACCAGGTTCTAAGTTCCACAAGCGTGAAGTTGTCGAAGCTGTCACCGTT
GTTGAC

181 -----+-----+-----+-----+-----+-----+ 240

CTGTCTGGTCCAAGATTCAAGGTGTTCGCACTTCAACAGCTTCGACAGTGGCAA
CAACTG

10

a D R P G S K F H K R E V V E A V T V V D -

15 ACTCCACCAGTTGTCGTTGTTGGTGTGTCGGTTACGTCGAAACCCCAAGAGGT
TTGAGA

241 -----+-----+-----+-----+-----+-----+ 300

TGAGGTGGTCAACAGCAACAACCACAACAGCCAATGCAGCTTTGGGGTTCTCC
AAACTCT

20

a T P P V V V V G V V G Y V E T P R G L R -

25 TCTTTGACCACCGTCTGGGCTGAACATTTGTCTGACGAAGTCAAGAGAAGATTC
TACAAG

301 -----+-----+-----+-----+-----+-----+ 360

AGAAACTGGTGGCAGACCCGACTTGTAACAGACTGCTTCAGTTCTCTTCTAAG
ATGTTC

30

a S L T T V W A E H L S D E V K R R F Y K -

35 AACTGGTACAAGTCTAAGAAGAAGGCTTTCACCAAATACTCTGCCAAGTACGCT
CAAGAT

361 -----+-----+-----+-----+-----+-----+ 420

TTGACCATGTTTCAGATTCTTCTTCCGAAAGTGGTTTATGAGACGGTTCATGCGA
GTTCTA

40

a N W Y K S K K K A F T K Y S A K Y A Q D -

45 GGTGCTGGTATTGAAAGAGAATTGGCTAGAATCAAGAAGTACGCTTCCGTCGTC
AGAGTT

421 -----+-----+-----+-----+-----+-----+ 480

CCACGACCATAACTTTCTCTTAACCGATCTTAGTTCTTCATGCGAAGGCAGCAG
TCTCAA

a G A G I E R E L A R I K K Y A S V V R V -

5 TTGGTCCCACTCAAATCAGAAAGACTCCATTGGCTCAAAAGAAGGCTCATTG
GCTGAA

481 -----+-----+-----+-----+-----+-----+ 540

10 AACCAGGTGTGAGTTTAGTCTTTCTGAGGTAACCGAGTTTCTCCGAGTAAAC
CGACTT

a L V H T Q I R K T P L A Q K K A H L A E -

15 ATCCAATTGAACGGTGGTTCCATCTCTGAAAAGGTTGACTGGGCTCGTGAACAT
TTCGAA

541 -----+-----+-----+-----+-----+-----+ 600

20 TAGGTTAACTTGCCACCAAGGTAGAGACTTTTCCAAGTACCCGAGCACTTGTA
AAGCTT

a I Q L N G G S I S E K V D W A R E H F E -

25 AAGACTGTTGCTGTCGACAGCGTTTTTTGAACAAAACGAAATGATTGACGCTATT
GCTGTC

601 -----+-----+-----+-----+-----+-----+ 660

30 TTCTGACAACGACAGCTGTCGCAAAAAGTTGTTTGGCTTTACTAACTGCGATAA
CGACAG

a K T V A V D S V F E Q N E M I D A I A V -

35 ACCAAGGGTCACGGTTTCGAAGGTGTTACCCACAGATGGGGTACTAAGAAATT
GCCAAGA

661 -----+-----+-----+-----+-----+-----+ 720

40 TGGTTCCCAGTGCCAAAGCTTCCACAATGGGTGTCTACCCCATGATTCTTTAAC
GGTTCT

a T K G H G F E G V T H R W G T K K L P R -

45 AAGACTCACAGAGGTCTAAGAAAGGTTGCTTGTATTGGTGCTTGGCATCCAGCC
CACGTT

721 -----+-----+-----+-----+-----+-----+ 780

TTCTGAGTGTCTCCAGATTCTTTCCAACGAACATAACCACGAACGGTAGGTCGG
GTGCAA

5 a K T H R G L R K V A C I G A W H P A H V -

ATGTGGAGTGTGTCAGAGCTGGTCAAAGAGGTTACCATTCCAGAACCTCCATT
AACCAC

10 781 -----+-----+-----+-----+-----+-----+ 840

TACACCTCACAACGGTCTCGACCAGTTTCTCCAATGGTAAGGTCTTGGAGGTAA
TTGGTG

15 a M W S V A R A G Q R G Y H S R T S I N H -

AAGATTTACAGAGTCGGTAAGGGTGATGATGAAGCTAACGGTGCTACCAGCTT
CGACAGA

20 841 -----+-----+-----+-----+-----+-----+ 900

TTCTAAATGTCTCAGCCATTCCCACTACTACTTCGATTGCCACGATGGTCTGAAGC
TGTCT

25 a K I Y R V G K G D D E A N G A T S F D R -

ACCAAGAAGACTATTACCCCAATGGGTGGTTTCGTCCACTACGGTGAAATTAAG
AACGAC

30 901 -----+-----+-----+-----+-----+-----+ 960

TGGTTCTTCTGATAATGGGGTTACCCACCAAAGCAGGTGATGCCACTTTAATTC
TTGCTG

35 a T K K T I T P M G G F V H Y G E I K N D -

TTCATCATGGTTAAAGGTTGTATCCCAGGTAACAGAAAGAGAATTGTTACTTTG
AGAAAG

40 961 -----+-----+-----+-----+-----+-----+ 1020

AAGTAGTACCAATTTCCAACATAGGGTCCATTGTCTTTCTCTTAACAATGAAAC
TCTTTC

45 a F I M V K G C I P G N R K R I V T L R K -

TCTTTGTACACCAACACTTCTAGAAAGGCTTTGGAAGAAGTCAGCTTGAAGTGG
ATTGAC

1021 -----+-----+-----+-----+-----+-----+ 1080

AGAAACATGTGGTTGTGAAGATCTTTCCGAAACCTTCTTCAGTCGAACTTCACC
TAACTG

5

a S L Y T N T S R K A L E E V S L K W I D -

ACTGCTTCTAAGTTCCGGTAAGGGTAGATTCCAAACCCCAGCTGAAAAGCATGCT
TTCATG

10

1081 -----+-----+-----+-----+-----+-----+ 1140

TGACGAAGATTCAAGCCATTCCCATCTAAGGTTTGGGGTCGACTTTTCGTACGA
AAGTAC

15

a T A S K F G K G R F Q T P A E K H A F M -

GGTACTTTGAAGAAGGACTTGTA

1141 -----+-----+---- 1164

20

CCATGAAACTTCTTCCTGAACATT

a G T L K K D L * -

L3 nucleic acids cloned from Arabidopsis and rice are described in Kim, *et al.*, Gene 93:177-182 (1990), and Nishi, *et al.*, Biochim. Biophys. Acta 1216:110-112 (1993) respectively. Tobacco contains two L3 genes. The nucleotide sequence and corresponding amino acid sequence for one tobacco L3 protein (the tobacco "8d" L3 protein) are set forth below:

25

ATGTCTCACAGGAAGTTTGAGCATCCAAGACACGGTTCTTTGGGATTTCTGCCC
AGGAAG

30

1 -----+-----+-----+-----+-----+-----+ 60

TACAGAGTGTCCTTCAAACCTCGTAGGTTCTGTGCCAAGAAACCCTAAAGACGGG
TCCTTC

35

a M S H R K F E H P R H G S L G F L P R K -

CGTGCTGCCAGACACAGGGGAAAGGTGAAGGCATTCCCAAAGATGATCCAAA
CAAGCCC

40

61 -----+-----+-----+-----+-----+-----+ 120

GCACGACGGTCTGTGTCCCCTTTCCACTTCGTAAGGGTTTTCTACTAGGTTTGT
TCGGG

45

a R A A R H R G K V K A F P K D D P N K P -

5 TGCAAGCTAACTGCCTTCTTGGGCTACAAAGCTGGCATGACTCACATTGTCAGA
GATGTT

121 -----+-----+-----+-----+-----+ 180

ACGTTTCGATTGACGGAAGAACCCGATGTTTCGACCGTACTGAGTGTAACAGTCT
CTACAA

10

a C K L T A F L G Y K A G M T H I V R D V -

15 GAAAAACCTGGATCAAACTCCACAAGAAAGAGACATGTGAAGCTGTCACCAT
CATTGAA

181 -----+-----+-----+-----+-----+ 240

CTTTTGGACCTAGTTTTGAGGTGTTCTTTCTCTGTACACTTCGACAGTGGTAGT
AACTT

20

a E K P G S K L H K K E T C E A V T I I E -

25 ACACCTCCAATGGTGATTGTTGGTGTGTTGGGTATGTGAAGACACCTCGTGGT
CTTCGT

241 -----+-----+-----+-----+-----+ 300

TGTGGAGGTTACCACTAACAACCACAACAACCCATACACTTCTGTGGAGCACCA
GAAGCA

30

a T P P M V I V G V V G Y V K T P R G L R -

35 TGCCTGAACACTGTCTGGGCTCAACATCTCAGTGAAGAGCTTAAGAGGAGGTTT
TACAAG

301 -----+-----+-----+-----+-----+ 360

ACGGACTTGTGACAGACCCGAGTTGTAGAGTCACTTCTCGAATTCTCCTCCAAG
ATGTTC

40

a C L N T V W A Q H L S E E L K R R F Y K -

45 AACTGGTGCAAGTCCAAGAAGAAGGCCTTCTTGAAATACTCCAAGAAATATGA
ATCTGAT

361 -----+-----+-----+-----+-----+ 420

TTGACCACGTTTCAGGTTCTTCTTCCGGAAGAACTTTATGAGGTTCTTTATACTTA
GACTA

a N W C K S K K K A F L K Y S K K Y E S D -

5 GAAGGGAAAAAGGACATCCAGACACAGCTGGAGAAATTGAAGAAGTATGCAT
GCGTCATC

421 -----+-----+-----+-----+-----+-----+ 480

10 CTTCCCTTTTTCCTGTAGGTCTGTGTCGACCTCTTTAACTTCTTCATACGTACGCA
GTAG

a E G K K D I Q T Q L E K L K K Y A C V I -

15 CGTGTTTTGGCTCACACTCAGATAAGGAAGATGAAGGGTCTGAAACAGAAGAA
AGCCCAT

481 -----+-----+-----+-----+-----+-----+ 540

20 GCACAAAACCGAGTGTGAGTCTATTCCTTCTACTTCCCAGACTTTGTCTTCTTTC
GGGTA

a R V L A H T Q I R K M K G L K Q K K A H -

25 TTGATGGAGATACAGGTGAATGGAGGGACAATTGCTCAGAAGGTTGACTTTGC
ATATGGT

541 -----+-----+-----+-----+-----+-----+ 600

30 AACTACCTCTATGTCCACTTACCTCCCTGTTAACGAGTCTTCCAACCTGAAACGTA
TACCA

a L M E I Q V N G G T I A Q K V D F A Y G -

35 TTCTTCGAGAAGCAGGTTCCAGTTGATGCTGTTTTTCAGAAGGATGAGATGATT
GACATC

601 -----+-----+-----+-----+-----+-----+ 660

40 AAGAAGCTCTTCGTCCAAGGTCAACTACGACAAAAAGTCTTCCTACTCTACTAA
CTGTAG

a F F E K Q V P V D A V F Q K D E M I D I -

45 ATTGGTGTCAACCAAGGGTAAGGGTTATGAAGGTGTTGTAACCTCGTTGGGGTGTG
ACACGT

661 -----+-----+-----+-----+-----+-----+ 720

TAACCACAGTGGTTCCCATTCCCAATACTTCCACAACATTGAGCAACCCACAC
TGTGCA

5 a I G V T K G K G Y E G V V T R W G V T R -

CTTCCTCGCAAAACCCACAGGGGTCTGCGTAAGGTTGCTTGTATTGGAGCCTGG
CACCT

10 721 -----+-----+-----+-----+-----+-----+ 780

GAAGGAGCGTTTTGGGTGTCCCCAGACGCATTCCAACGAACATAACCTCGGACC
GTGGGA

15 a L P R K T H R G L R K V A C I G A W H P -

GCTAGAGTTTCCTACACAGTTGCCCCGTGCTGGTCAAATGGATACCATCACCGT
ACCGAG

20 781 -----+-----+-----+-----+-----+-----+ 840

CGATCTCAAAGGATGTGTCAACGGGCACGACCAGTTTTACCTATGGTAGTGGCA
TGGCTC

25 a A R V S Y T V A R A G Q N G Y H H R T E -

ATGAACAAGAAGGTTTACAACTAGGGAAGGCTGGCCAAGAGTCCCATGCTGC
TGTAAT

30 841 -----+-----+-----+-----+-----+-----+ 900

TACTTGTTCTTCCAAATGTTTGATCCCTTCCGACCGGTTCTCAGGGTACGACGAC
ATTGA

35 a M N K K V Y K L G K A G Q E S H A A V T -

GATTTTGACAGGACCGAGAAAGACATTACTCCCATGGGTGGATTTCCCCATTAT
GGTGTG

40 901 -----+-----+-----+-----+-----+-----+ 960

CTAAAACTGTCCTGGCTCTTTCTGTAATGAGGGTACCCACCTAAAGGGGTAATA
CCACAC

45 a D F D R T E K D I T P M G G F P H Y G V -

GTGAAGGATGATTACCTGTTGATCAAGGGATGCTGTGTTGGTCCTAAGAAGAGG
GTTGTA

961 -----+-----+-----+-----+-----+-----+ 1020

CACTTCCTACTAATGGACAACCTAGTTCCTACGACACAACCAGGATTCTTCTCC
CAACAT

5

a V K D D Y L L I K G C C V G P K K R V V -

ACCCTTCGTCAGTCCCTGCTCAACCAGACCTCTCGTGTCTGCTCTTGAGGAGATTA
AGCTG

10

1021 -----+-----+-----+-----+-----+-----+ 1080

TGGGAAGCAGTCAGGGACGAGTTGGTCTGGAGAGCACAGCGAGAACTCCTCTA
ATTCGAC

15

a T L R Q S L L N Q T S R V A L E E I K L -

AAGTTCATCGATACATCCTCAAAGTTTGGACATGGTTCGCTTCCAGACCACTCAA
GAGAAG

20

1081 -----+-----+-----+-----+-----+-----+ 1140

TTCAAGTAGCTATGTAGGAGTTTCAAACCTGTACCAGCGAAGGTCTGGTGAGTT
CTCTTC

25

a K F I D T S S K F G H G R F Q T T Q E K -

CAGAAATTCTATGGCCGGTTGAAGGGTTAA

1141 -----+-----+-----+ 1170

30

GTCTTTAAGATACCGGCCAACTTCCCAATT

a Q K F Y G R L K G * -

The nucleotide sequence and corresponding amino acid sequence for the second tobacco L3
protein (the tobacco "10d" L3 protein) are set forth below.

35

ATGTCGCATCGCAAGTTTGAGCACCCAAGACACGGTTCTTTGGGATTTCTTCCA
AGGAAA

1 -----+-----+-----+-----+-----+-----+ 60

40

TACAGCGTAGCGTTCAAACCTCGTGGGTTCTGTGCCAAGAAACCCTAAAGAAGGT
TCCTTT

a M S H R K F E H P R H G S L G F L P R K -

45

AGAGCAGCACGACACAGGGGCAAAGTGAAGGCTTTTCCCAAAGATGATACAAC
AAAACCT

61 -----+-----+-----+-----+-----+-----+ 120

TCTCGTCGTGCTGTGTCCCCGTTTCACTTCCGAAAAGGGTTTCTACTATGTTGTT
TTGGA

5

a R A A R H R G K V K A F P K D D T T K P -

TGCAGGTTGACAGCTTTCCTTGGCTACAAAGCTGGTATGACTCATATTGTCAGA
GATGTT

10

121 -----+-----+-----+-----+-----+-----+ 180

ACGTCCAAC TGTGAAAGGAACCGATGTTTCGACCATACTGAGTATAACAGTCT
CTACAA

15

a C R L T A F L G Y K A G M T H I V R D V -

GAAAAAC CAGGGTCAAACTCCATAAGAAAGAAACATGCGAACTGGTTACCAT
AATTGAA

20

181 -----+-----+-----+-----+-----+-----+ 240

CTTTTTGGTCCCAGTTTTGAGGTATTCTTTCTTTGTACGCTTGACCAATGGTATTA
ACTT

25

a E K P G S K L H K K E T C E L V T I I E -

ACGCCCTCCTATGATTGTTGTTGGGGTTGTTGGCTATGTGAAAACACCACGTGGC
CTTCGC

30

241 -----+-----+-----+-----+-----+-----+ 300

TGCGGAGGATACTAACAACAACCCCAACAACCGATACACTTTTGTGGTGCACCG
GAAGCG

35

a T P P M I V V G V V G Y V K T P R G L R -

TGCCTTAGCACGGTCTGGGCTCAACATCTTAGTGAAGAGATTAAAAGGAGATTC
TACAAG

40

301 -----+-----+-----+-----+-----+-----+ 360

ACGGAATCGTGCCAGACCCGAGTTGTAGAATCACTTCTCTAATTTTCCTCTAAG
ATGTTC

45

a C L S T V W A Q H L S E E I K R R F Y K -

AACTGGTGCATGTCCAAAAAGAAGGCCTTTGCAAAGTACTCGAAGAAGTATGA
AACTGAT

361 -----+-----+-----+-----+-----+-----+ 420

TTGACCACGTACAGGTTTTTCTTCCGGAAACGTTTCATGAGCTTCTTCATACTTT
GACTA

a N W C M S K K K A F A K Y S K K Y E T D -

GATGGTAAGAAGGATATTAATGCGCAATTGGAGAAGATGAAGAAGTATTGTTG
TGTCATT

421 -----+-----+-----+-----+-----+-----+ 480

CTACCATTCTTCCTATAATTACGCGTTAACCTCTTCTACTTCTTCATAACAACAC
AGTAA

a D G K K D I N A Q L E K M K K Y C C V I -

CGTGTTTTGGCCCATACTCAGATTAGAAAAATGAAAGGTCTCAAGCAAAAGAA
GGCACAT

481 -----+-----+-----+-----+-----+-----+ 540

GCACAAAACCGGGTATGAGTCTAATCTTTTTACTTTCCAGAGTTCGTTTTCTTCC
GTGTA

a R V L A H T Q I R K M K G L K Q K K A H -

CTGATGGAGATTTCAGGTTAATGGTGGGGATGTTTCCCAGAAGGTTGATTATGCT
TATGGC

541 -----+-----+-----+-----+-----+-----+ 600

GACTACCTCTAAGTCCAATTACCACCCCTACAAAGGGTCTTCCAACCTAATACGA
ATACCG

a L M E I Q V N G G D V S Q K V D Y A Y G -

TTCTTTGAGAAGCAGATTCCTGTTGATGCTATTTTCCAAAAGGATGAGATGATC
GATATT

601 -----+-----+-----+-----+-----+-----+ 660

AAGAACTCTTCGTCTAAGGACAACCTACGATAAAAGGTTTTCTACTCTACTAG
CTATAA

a F F E K Q I P V D A I F Q K D E M I D I -

ATTGGTGTGACCAAAGGTAAGGGTTATGAGGGTGTGGTGACTCGTTGGGGTGTA
ACCCGT

5 661 -----+-----+-----+-----+-----+ 720

TAACCACACTGGTTTCCATTCCCAATACTCCCACACCACTGAGCAACCCACAT
TGGGCA

10 a I G V T K G K G Y E G V V T R W G V T R -

CTCCACGTAAAGACCCATCGTGGTCTTAGAAAGGTGGCTTGTATTGGTGCTTGG
CATCCA

15 721 -----+-----+-----+-----+-----+ 780

GAGGGTGCATTCTGGGTAGCACCAGAATCTTTCCACCGAACATAACCACGAACC
GTAGGT

20 a L P R K T H R G L R K V A C I G A W H P -

GCACGGGTGTCATACACTGTAGCTAGGGCTGGGCAGAATGGTTATCACCATCGC
ACTGAG

25 781 -----+-----+-----+-----+-----+ 840

CGTGCCACAGTATGTGACATCGATCCCGACCCGTCTTACCAATAGTGGTAGCG
TGACTC

30 a A R V S Y T V A R A G Q N G Y H H R T E -

CTGAACAAGAAAGTCTACAGGCTGGGCAAGGCTGGTCAGGAGTCTCATTCTGC
AATAACT

35 841 -----+-----+-----+-----+-----+ 900

GACTTGTTCTTTCAGATGTCCGACCCGTTCCGACCAGTCCTCAGAGTAAGACGT
TATTGA

40 a L N K K V Y R L G K A G Q E S H S A I T -

GAGTTTGACAGGACTGAGAAGGATATCACGCCAATGGGTGGATTTCTCATTAT
GGTATT

45 901 -----+-----+-----+-----+-----+ 960

CTCAAAGTGCCTGACTCTTCCTATAGTGCGGTTACCCACCTAAAGGAGTAATA
CCATAA

a E F D R T E K D I T P M G G F P H Y G I -

5 GTGAAAGAAGACTTTCTGTTGATTAAGGGCTGCTGTGTTGGACCAAAGAAGCGT
GTTGTG

961 -----+-----+-----+-----+-----+-----+ 1020

CACTTCTTCTGAAAGACAACCTAATCCCGACGACACAACCTGGTTTCTTCGCA
CAACAC

10

a V K E D F L L I K G C C V G P K K R V V -

15 ACTCTGAGGCAGTCTCTGTTGAATCAGACATCTAGGGTTGCATTGGAGGAGATC
AAGCTC

1021 -----+-----+-----+-----+-----+-----+ 1080

TGAGACTCCGTCAGAGACAACCTTAGTCTGTAGATCCCAACGTAACCTCCTCTAG
TTCGAG

20

a T L R Q S L L N Q T S R V A L E E I K L -

25 AAGTTCATTGACACATCCTCCAAGTTTGGCCATGGACGCTTCCAGACTACACAG
GAGAAG

1081 -----+-----+-----+-----+-----+-----+ 1140

TTCAAGTAACTGTGTAGGAGGTTCAAACCGGTACCTGCGAAGGTCTGATGTGTC
CTCTTC

30

a K F I D T S S K F G H G R F Q T T Q E K -

GACAAATTCTATGGACGCTCTTAAAGCTTGA

1141 -----+-----+-----+ 1170

35 CTGTTTAAGATACCTGCAGAATTTCTGAACT

a D K F Y G R L K A * -

The nucleotide sequence and corresponding amino acid sequence for a
spontaneously occurring mutant L3 gene obtained from the yeast *Saccharomyces cerevisiae*
40 (the L3 trichodermin resistance mutant (tcm1)) are set forth below. One nucleotide change
G765C results in the amino acid change W255C (Trp255Cys). See, Schultz, *et al.*, J.
Bacteriol. 155:8-14 (1983).

45 ATGTCTCACAGAAAGTACGAAGCACCGTCACGGTCATTTAGGTTTCTTGCCA
AGAAAG

1 -----+-----+-----+-----+-----+-----+ 60

TACAGAGTGTCTTTCATGCTTCGTGGTGCAGTGCCAGTAAATCCAAAGAACGGT
TCTTTC

5 a M S H R K Y E A P R H G H L G F L P R K -

AGAGCTGCCTCCATCAGAGCTAGAGTTAAGGCTTTTCCAAAGGATGACAGATCC
AAGCCA

10 61 -----+-----+-----+-----+-----+-----+ 120

TCTCGACGGAGGTAGTCTCGATCTCAATTCCGAAAAGGTTTCCTACTGTCTAGG
TTCGGT

15 a R A A S I R A R V K A F P K D D R S K P -

GTTGCTCTAACTTCCTTCTTGGGTTACAAGGCTGGTATGACCACCATTGTCAGAG
ATTG

20 121 -----+-----+-----+-----+-----+-----+ 180

CAACGAGATTGAAGGAAGAACCCAATGTTCCGACCATACTGGTGGTAACAGTC
TCTAAAC

25 a V A L T S F L G Y K A G M T T I V R D L -

GACAGACCAGGTTCTAAGTTCCACAAGCGTGAAGTTGTCGAAGCTGTCACCGTT
GTTGAC

30 181 -----+-----+-----+-----+-----+-----+ 240

CTGTCTGGTCCAAGATTCAAGGTGTTCGCACTTCAACAGCTTCGACAGTGGCAA
CAACTG

35 a D R P G S K F H K R E V V E A V T V V D -

ACTCCACCAGTTGTCGTTGTTGGTGTGTCGGTTACGTCGAAACCCCAAGAGGT
TTGAGA

40 241 -----+-----+-----+-----+-----+-----+ 300

TGAGGTGGTCAACAGCAACAACCACAACAGCCAATGCAGCTTTGGGGTTCTCC
AAACTCT

45 a T P P V V V V G V V G Y V E T P R G L R -

TCTTTGACCACCGTCTGGGCTGAACATTTGTCTGACGAAGTCAAGAGAAGATTC
TACAAG

301 -----+-----+-----+-----+-----+-----+ 360

AGAAACTGGTGGCAGACCCGACTTGTAACAGACTGCTTCAGTTCTCTTCTAAG
ATGTTC

5

a S L T T V W A E H L S D E V K R R F Y K -

AACTGGTACAAGTCTAAGAAGAAGGCTTTCACCAAATACTCTGCCAAGTACGCT
CAAGAT

10

361 -----+-----+-----+-----+-----+-----+ 420

TTGACCATGTTTCAGATTCTTCTTCCGAAAGTGGTTTATGAGACGGTTCATGCGA
GTTCTA

15

a N W Y K S K K K A F T K Y S A K Y A Q D -

GGTGCTGGTATTGAAAGAGAATTGGCTAGAATCAAGAAGTACGCTTCCGTCGTC
AGAGTT

20

421 -----+-----+-----+-----+-----+-----+ 480

CCACGACCATAACTTTCTCTTAACCGATCTTAGTTCTTCATGCGAAGGCAGCAG
TCTCAA

25

a G A G I E R E L A R I K K Y A S V V R V -

TTGGTCCACACTCAAATCAGAAAGACTCCATTGGCTCAAAAGAAGGCTCATTTG
GCTGAA

30

481 -----+-----+-----+-----+-----+-----+ 540

AACCAGGTGTGAGTTTAGTCTTTCTGAGGTAACCGAGTTTTCTTCCGAGTAAAC
CGACTT

35

a L V H T Q I R K T P L A Q K K A H L A E -

ATCCAATTGAACGGTGGTTCCATCTCTGAAAAGGTTGACTGGGCTCGTGAACAT
TTCGAA

40

541 -----+-----+-----+-----+-----+-----+ 600

TAGGTAACTTGCCACCAAGGTAGAGACTTTTCCAAGTACCCGAGCACTTGTA
AAGCTT

45

a I Q L N G G S I S E K V D W A R E H F E -

AAGACTGTTGCTGTCGACAGCGTTTTTGAACAAAACGAAATGATTGACGCTATT
GCTGTC

601 -----+-----+-----+-----+-----+-----+ 660

TTCTGACAACGACAGCTGTCGCAAAACTTGTTTTGCTTTACTAACTGCGATAA
CGACAG

a K T V A V D S V F E Q N E M I D A I A V -

ACCAAGGGTCACGGTTTCGAAGGTGTTACCCACAGATGGGGTACTAAGAAATT
GCCAAGA

661 -----+-----+-----+-----+-----+-----+ 720

TGGTTCCCAGTGCCAAAGCTTCCACAATGGGTGTCTACCCCATGATTCTTTAAC
GGTTCT

a T K G H G F E G V T H R W G T K K L P R -

AAGACTCACAGAGGTCTAAGAAAGGTGCTTGTATTGGTGCTTGCCATCCAGCC
CACGTT

721 -----+-----+-----+-----+-----+-----+ 780

TTCTGAGTGTCTCCAGATTCTTTCCAACGAACATAACCACGAACGGTAGGTCCG
GTGCAA

a K T H R G L R K V A C I G A C H P A H V -

ATGTGGAGTGTTGCCAGAGCTGGTCAAAGAGGTACCATTCCAGAACCTCCATT
AACCAC

781 -----+-----+-----+-----+-----+-----+ 840

TACACCTCACAACGGTCTCGACCAGTTTCTCCAATGGTAAGGTCTTGGAGGTAA
TTGGTG

a M W S V A R A G Q R G Y H S R T S I N H -

AAGATTTACAGAGTCGGTAAGGGTGATGATGAAGCTAACGGTGCTACCAGCTT
CGACAGA

841 -----+-----+-----+-----+-----+-----+ 900

TTCTAAATGTCTCAGCCATTCCCCTACTACTTCGATTGCCACGATGGTCGAAGC
TGTCT

a K I Y R V G K G D D E A N G A T S F D R -

ACCAAGAAGACTATTACCCCAATGGGTGGTTTCGTCCACTACGGTGAAATTAAG
AACGAC

5 901 -----+-----+-----+-----+-----+-----+ 960

TGGTTCTTCTGATAATGGGGTTACCCACCAAAGCAGGTGATGCCACTTTAATTC
TTGCTG

10 a T K K T I T P M G G F V H Y G E I K N D -

TTCATCATGGTTAAAGGTTGTATCCCAGGTAACAGAAAGAGAATTGTTACTTTG
AGAAAG

15 961 -----+-----+-----+-----+-----+-----+ 1020

AAGTAGTACCAATTTCCAACATAGGGTCCATTGTCTTTCTCTTAACAATGAAAC
TCTTTC

20 a F I M V K G C I P G N R K R I V T L R K -

TCTTTGTACACCAACACTTCTAGAAAGGCTTTGGAAGAAGTCAGCTTGAAGTGG
ATTGAC

25 1021 -----+-----+-----+-----+-----+-----+ 1080

AGAAACATGTGGTTGTGAAGATCTTTCCGAAACCTTCTTCAGTCGAACTTCACC
TAACTG

30 a S L Y T N T S R K A L E E V S L K W I D -

ACTGCTTCTAAGTTCGGTAAGGGTAGATTCCAAACCCCAGCTGAAAAGCATGCT
TTCATG

35 1081 -----+-----+-----+-----+-----+-----+ 1140

TGACGAAGATTCAAGCCATTCCCATCTAAGGTTTGGGGTCGACTTTTCGTACGA
AAGTAC

40 a T A S K F G K G R F Q T P A E K H A F M -

GGTACTTTGAAGAAGGACTTGTA
1141 -----+-----+----- 1164
CCATGAAACTTCTTCCTGAACATT

45 a G T L K K D L * -

Several naturally occurring fungal toxins, including trichodermin, exert a cytotoxic effect by targeting the peptidyltransferase step of elongation during protein synthesis. The fungal

toxin trichodermin, for example, inhibits peptide bond formation by binding to the peptidyltransferase center (Barbacid, *et al.*, Eur. J. Biochem. 44:437-444 (1974). In the case of anti-fungal resistance, therefore, other spontaneously occurring L3 mutants may be identified simply by determining whether cells survive in the presence of a given fungal toxin. See Fried, *et al.*, Proc. Natl. Acad. Sci. USA 78:238-242 (1981).

Non-naturally occurring L3 mutants useful in the present invention can be identified and selected in several ways based upon one or more of several properties that they exhibit. One protocol entails randomly mutagenizing the L3 gene, introducing nucleic acid encoding the single chain RIP such as Pokeweed Antiviral Protein (PAP) into the microorganism strains harboring L3 gene, and determining if the mutant L3 confers resistance to the cytostatic effects of PAP. In preferred embodiments, isogenic null mutant strains wherein the endogenous L3 gene has been knocked out are transformed with a *LEU2*-based vector, e.g., pNT 188, containing a PAP cDNA under the control of a *GAL1* promoter and plasmids containing the mutated L3 DNAs. Galactose induction of PAP expression does not have a cytostatic effect on the growth of the strain harboring the L3 mutant that confers resistance to PAP. In contrast, growth of cells harboring PAP DNA and wild-type L3 DNA is significantly inhibited when PAP expression is induced by galactose. Stated differently, cells harboring the L3 mutants will grow under PAP induction, whereas cells containing pRPL3 encoding wild-type L3 will not grow.

Another method of selecting L3 mutants is based on the phenomenon that maintenance of killer ("Mak") alleles are unable to maintain the M1 satellite virus. Wickner, *et al.*, PNAS USA 79:4706-4708 (1982). M1 is an endogenous virus that is found in most naturally occurring yeast strains. It encodes a secreted toxin and an immunity factor. Yeast cells harboring M1 are able to kill cells that do not contain the virus. Such infected cells are called "killer" yeast. The ability of infected cells to kill uninfected cells is easily ascertained through a simple assay. Similarly, loss of such "killer" activity can also be monitored. These results indicate that ribosomal protein L3 is involved in the replication and maintenance of the M1 double stranded RNA of the yeast killer virus. Thus, using a killer virus assay (e.g., Tumer, *et al.*, J. Virol. 72:1036-1042 (1998)) allows for the determination whether the L3 mutants can maintain the killer virus. The L3 mutants of the present invention are identified by their inability to maintain the yeast killer virus (L-A-M1).

Yet another method is based upon the observation that strains harboring the Mak8-1 allele of RPL3 exhibit increased programmed frameshifting efficiencies, supporting

the notion that events at the peptidyltransferase center play a critical role in programmed -1 ribosomal frameshifting. Thus, the desired L3 mutants exhibit altered programmed -1 ribosomal frameshifting efficiencies both in cells and in *in vitro* translation extracts as determined by the assays described in Tumer, *et al.*, (1998) *supra*. In many cases, the mutants exhibit increased efficiencies but in some cases, decreased efficiencies are observed.

L3 mutants may also exhibit resistance to peptidyltransferase inhibitors. Such inhibitors include sparsomycin, anicomycin, puromycin, tridermin, pristinamycin, gougerotinomycin, lincomycin and clindamycin. Methods for determining whether an L3 mutant is resistant are described in Example 2.

The nucleotide and corresponding amino acid sequences for one Mak mutant of L3 are set forth below. Two nucleotide changes, G765C and C769T, result in two amino acid changes, namely W255C (Trp255Cys) and P257S (Pro257Ser) respectively. This mutant L3 is designated Mak8 (W255C, P257S).

ATGTCTCACAGAAAGTACGAAGCACCGTCACGGTCATTTAGGTTTCTTGCCA
AGAAAG

1 -----+-----+-----+-----+-----+-----+ 60

TACAGAGTGTCTTTCATGCTTCGTGGTGCAGTGCCAGTAAATCCAAAGAACGGT
TCTTTC

a M S H R K Y E A P R H G H L G F L P R K -

AGAGCTGCCTCCATCAGAGCTAGAGTTAAGGCTTTTCCAAAGGATGACAGATCC
AAGCCA

61 -----+-----+-----+-----+-----+-----+ 120

TCTCGACGGAGGTAGTCTCGATCTCAATTCCGAAAAGGTTTCCTACTGTCTAGG
TTCGGT

a R A A S I R A R V K A F P K D D R S K P -

GTTGCTCTAACTTCCTTCTTGGGTTACAAGGCTGGTATGACCACCATTTGTCAGAG
ATTTG

121 -----+-----+-----+-----+-----+-----+ 180

CAACGAGATTGAAGGAAGAACCCAATGTTCCGACCATACTGGTGGTAACAGTC
TCTAAAC

a V A L T S F L G Y K A G M T T I V R D L -

GACAGACCAGGTTCTAAGTTCCACAAGCGTGAAGTTGTCGAAGCTGTCACCGTT
5 GTTGAC

181 -----+-----+-----+-----+-----+-----+ 240

CTGTCTGGTCCAAGATTCAAGGTGTTTCGCACTTCAACAGCTTCGACAGTGGCAA
CAACTG

10 a D R P G S K F H K R E V V E A V T V V D -

ACTCCACCAGTTGTCGTTGTTGGTGTTCGGTTACGTCGAAACCCCAAGAGGT
15 TTGAGA

241 -----+-----+-----+-----+-----+-----+ 300

TGAGGTGGTCAACAGCAACAACCACAACAGCCAATGCAGCTTTGGGGTTCTCC
AAACTCT

20 a T P P V V V V G V V G Y V E T P R G L R -

TCTTTGACCACCGTCTGGGCTGAACATTTGTCTGACGAAGTCAAGAGAAGATTC
25 TACAAG

301 -----+-----+-----+-----+-----+-----+ 360

AGAAACTGGTGGCAGACCCGACTTGTAACAGACTGCTTCAGTTCTCTTCTAAG
ATGTTC

30 a S L T T V W A E H L S D E V K R R F Y K -

AACTGGTACAAGTCTAAGAAGAAGGCTTTCACCAAATACTCTGCCAAGTACGCT
35 CAAGAT

361 -----+-----+-----+-----+-----+-----+ 420

TTGACCATGTTCAGATTCTTCTTCCGAAAGTGGTTTATGAGACGGTTCATGCGA
GTCTA

40 a N W Y K S K K K A F T K Y S A K Y A Q D -

GGTGCTGGTATTGAAAGAGAATTGGCTAGAATCAAGAAGTACGCTTCCGTCGTC
45 AGAGTT

421 -----+-----+-----+-----+-----+-----+ 480

CCACGACCATAACTTTCTCTTAACCGATCTTAGTTCTTCATGCGAAGGCAGCAG
TCTCAA

a G A G I E R E L A R I K K Y A S V V R V -

5 TTGGTCCACACTCAAATCAGAAAGACTCCATTGGCTCAAAAGAAGGCTCATTTG
GCTGAA

481 -----+-----+-----+-----+-----+-----+ 540

10 AACCAGGTGTGAGTTTAGTCTTTCTGAGGTAACCGAGTTTCTTCCGAGTAAAC
CGACTT

a L V H T Q I R K T P L A Q K K A H L A E -

15 ATCCAATTGAACGGTGGTTCCATCTCTGAAAAGGTTGACTGGGCTCGTGAACAT
TTCGAA

541 -----+-----+-----+-----+-----+-----+ 600

20 TAGGTTAACTTGCCACCAAGGTAGAGACTTTTCCAAGTACCCGAGCACTTGTA
AAGCTT

a I Q L N G G S I S E K V D W A R E H F E -

25 AAGACTGTTGCTGTCGACAGCGTTTTTTGAACAAAACGAAATGATTGACGCTATT
GCTGTC

601 -----+-----+-----+-----+-----+-----+ 660

30 TTCTGACAACGACAGCTGTCGCAAAAAGTTGTTTTGCTTTACTAACTGCGATAA
CGACAG

a K T V A V D S V F E Q N E M I D A I A V -

35 ACCAAGGGTCACGGTTTCGAAGGTGTTACCCACAGATGGGGTACTAAGAAATT
GCCAAGA

661 -----+-----+-----+-----+-----+-----+ 720

40 TGGTTCACAGTGCCAAAGCTTCCACAATGGGTGTCTACCCCATGATTCTTTAAC
GGTTCT

a T K G H G F E G V T H R W G T K K L P R -

45 AAGACTCACAGAGGTCTAAGAAAGGTTGCTTGTATTGGTGCTTGCCATTCAGCC
CACGTT

721 -----+-----+-----+-----+-----+-----+ 780

TTCTGAGTGTCTCCAGATTCTTTCCAACGAACATAACCACGAACGGTAGGTCGG
GTGCAA

5 a K T H R G L R K V A C I G A C H S A H V -

ATGTGGAGTGTTGCCAGAGCTGGTCAAAGAGGTTACCATTCAGAACCTCCATT
AACCAC

10 781 -----+-----+-----+-----+-----+-----+ 840

TACACCTCACAACGGTCTCGACCAGTTTCTCCAATGGTAAGGTCTTGGAGGTAA
TTGGTG

15 a M W S V A R A G Q R G Y H S R T S I N H -

AAGATTTACAGAGTCGGTAAGGGTGATGATGAAGCTAACGGTGCTACCAGCTT
CGACAGA

20 841 -----+-----+-----+-----+-----+-----+ 900

TTCTAAATGTCTCAGCCATTCCCCTACTACTTCGATTGCCACGATGGTCTGAAGC
TGCTCT

25 a K I Y R V G K G D D E A N G A T S F D R -

ACCAAGAAGACTATTACCCCAATGGGTGGTTTCGTCCACTACGGTGAAATTAAG
AACGAC

30 901 -----+-----+-----+-----+-----+-----+ 960

TGGTTCTTCTGATAATGGGGTTACCCACCAAAGCAGGTGATGCCACTTTAATTC
TTGCTG

35 a T K K T I T P M G G F V H Y G E I K N D -

TTCATCATGGTTAAAGGTTGTATCCCAGGTAACAGAAAGAGAATTGTTACTTTG
AGAAAG

40 961 -----+-----+-----+-----+-----+-----+ 1020

AAGTAGTACCAATTTCCAACATAGGGTCCATTGTCTTTCTCTTAACAATGAAAC
TCTTTC

45 a F I M V K G C I P G N R K R I V T L R K -

TCTTTGTACACCAACACTTCTAGAAAGGCTTTGGAAGAAGTCAGCTTGAAGTGG
ATTGAC

1021 -----+-----+-----+-----+-----+-----+ 1080

AGAAACATGTGGTTGTGAAGATCTTTCCGAAACCTTCTTCAGTCGAACTTCACC
TAACTG

5

a S L Y T N T S R K A L E E V S L K W I D -

ACTGCTTCTAAGTTCGGTAAGGGTAGATTCCAAACCCCAGCTGAAAAGCATGCT
TTCATG

10

1081 -----+-----+-----+-----+-----+-----+ 1140

TGACGAAGATTCAAGCCATTCCCATCTAAGGTTTGGGGTCGACTTTTCGTACGA
AAGTAC

15

a T A S K F G K G R F Q T P A E K H A F M -

GGTACTTTGAAGAAGGACTTGTA

1141 -----+-----+----- 1164

20

CCATGAAACTTCTTCCTGAACATT

a G T L K K D L * -

The nucleotide and corresponding amino acid sequences for another L3
mutant ("rpl-T845C") are set forth below. One nucleotide change, T845C, results in the
amino acid change I282T (Iso282Thr).

25

ATGTCTCACAGAAAGTACGAAGCACCGTCACGGTCATTTAGGTTTCTTGCCAAGAAAG

1 -----+-----+-----+-----+-----+-----+ 60

-----+ 60

30

TACAGAGTGTCTTTCATGCTTCGTGGTGCAGTGCCAGTAAATCCAAAGAACGGTTCTTTC

a M S H R K Y E A P R H G H L G F L P
R K -

35

AGAGCTGCCTCCATCAGAGCTAGAGTTAAGGCTTTTCCAAAGGATGACAGATCCAAGCCA

61 -----+-----+-----+-----+-----+-----+ 120

-----+ 120

40

TCTCGACGGAGGTAGTCTCGATCTCAATTCCGAAAAGGTTTCCTACTGTCTAGGTTCCGGT

a R A A S I R A R V K A F P K D D R S
K P -

45

GTTGCTCTAACTTCCTTCTTGGGTTACAAGGCTGGTATGACCACCATTGTCAGAGATTTG

121 -----+-----+-----+-----+-----+-----+-----
-----+ 180

5

CAACGAGATTGAAGGAAGAACCCAATGTTCCGACCATACTGGTGGTAACAGTCTCTAAAC

a V A L T S F L G Y K A G M T T I V R
D L -

10

GACAGACCAGGTTCTAAGTTCCACAAGCGTGAAGTTGTCGAAGCTGTCACCGTTGTTGAC

181 -----+-----+-----+-----+-----+-----+-----
-----+ 240

15

CTGTCTGGTCCAAGATTCAAGGTGTTGCGACTTCAACAGCTTCGACAGTGGCAACAAC

a D R P G S K F H K R E V V E A V T V
V D -

20

ACTCCACCAGTTGTCGTTGTTGGTGTGTCGGTTACGTCGAAACCCCAAGAGGTTTGAGA

241 -----+-----+-----+-----+-----+-----+-----
-----+ 300

25

TGAGGTGGTCAACAGCAACAACCACAACAGCCAATGCAGCTTTGGGGTTCTCCAAACTCT

a T P P V V V V G V V G Y V E T P R G
L R -

30

TCTTTGACCACCGTCTGGGCTGAACATTTGTCTGACGAAGTCAAGAGAAGATTCTACAAG

301 -----+-----+-----+-----+-----+-----+-----
-----+ 360

35

AGAAACTGGTGGCAGACCCGACTTGTAACAGACTGCTTCAGTTCTCTTCTAAGATGTTT

a S L T T V W A E H L S D E V K R R F
Y K -

40

AACTGGTACAAGTCTAAGAAGAAGGCTTTCACCAAATACTCTGCCAAGTACGCTCAAGAT

361 -----+-----+-----+-----+-----+-----+-----
-----+ 420

45

TTGACCATGTTTCAGATTCTTCTTCCGAAAGTGGTTTATGAGACGGTTCATGCGAGTTCTA

a N W Y K S K K K A F T K Y S A K Y A
Q D -

50

GGTGCTGGTATTGAAAGAGAATTGGCTAGAATCAAGAAGTACGCTTCCGTCGTCAGAGTT
421 -----+-----+-----+-----+-----+---
-----+ 480

CCACGACCATAACTTTCTCTTAACCGATCTTAGTTCTTCATGCGAAGGCAGCAGTCTCAA

a G A G I E R E L A R I K K Y A S V V
R V -

TTGGTCCACACTCAAATCAGAAAGACTCCATTGGCTCAAAAGAAGGCTCATTGCTGAA
481 -----+-----+-----+-----+-----+---
-----+ 540

AACCAGGTGTGAGTTTAGTCTTTCTGAGGTAACCGAGTTTCTTCCGAGTAAACCGACTT

a L V H T Q I R K T P L A Q K K A H L
A E -

ATCCAATTGAACGGTGGTTCCATCTCTGAAAAGGTTGACTGGGCTCGTGAACATTTGCGAA
541 -----+-----+-----+-----+-----+---
-----+ 600

TAGGTTAACTTGCCACCAAGGTAGAGACTTTTCCAAGTACCCGAGCACTTGTAAGCTT

a I Q L N G G S I S E K V D W A R E H
F E -

AAGACTGTTGCTGTCGACAGCGTTTTTGAACAAAACGAAATGATTGACGCTATTGCTGTC
601 -----+-----+-----+-----+-----+---
-----+ 660

TTCTGACAACGACAGCTGTCGCAAAACTTGTTTTGCTTTACTAACTGCGATAACGACAG

a K T V A V D S V F E Q N E M I D A I
A V -

ACCAAGGGTCACGGTTTCGAAGGTGTTACCCACAGATGGGGTACTAAGAAATTGCCAAGA
661 -----+-----+-----+-----+-----+---
-----+ 720

TGGTTCCCAGTGCCAAAGCTTCCACAATGGGTGTCTACCCCATGATTCTTTAACGGTTCT

a T K G H G F E G V T H R W G T K K L
P R -

10

15

20

25

30

35

40

45

50

a S L Y T N T S R K A L E E V S L K W
I D -

ACTGCTTCTAAGTTTCGGTAAGGGTAGATTCCAAACCCCAGCTGAAAAGCATGCTTTCATG
1081 -----+-----+-----+-----+-----+-----+-----
-----+ 1140

a T A S K F G K G R F Q T P A E K H A
F M -

GGTACTTTGAAGAAGGACTTGTA
1141 -----+-----+----- 1164
CCATGAAACTTCTTCCTGAACATT

a G T L K K D L * -

The L3 nucleic acids of the present invention can be prepared in accordance with standard procedures. Likewise, preparation of expression cassettes and vectors for the introduction of the L3 nucleic acid into plant cells, protoplasts, whole plants and plant parts are also well known in the art. In the case of monocot transformation, for example, preferred promoters include the CaMV 35S promoter, ubiquitin promoter, and the actin promoter. The L3 proteins *per se* may be produced in accordance with standard techniques, preferably via genetic engineering.

In other preferred embodiments, nucleic acids encoding L3 and L3 mutants are introduced into plants in concert with wild-type PAP, variant PAP (i.e. PAP- ν , which differs from wild-type PAP in terms of the double amino acid substitutions, Leu20Arg and Tyr49His), PAP mutants having reduced phytotoxicity compared to wild-type PAP or PAP- ν , and which have intact catalytic active site amino acid residues (Glu176 and Arg179), and PAP II. Wild-type PAP, PAP- ν and various PAP mutants are described in U.S. Patents 5,756,322 and 5,880,322. PAP II is reported in Poyet, *et al.*, FEBS Letters 347:268-272 (1994). The term "PAP-II," is inclusive of the 310 amino acid polypeptide disclosed in Poyet *et al.*, the 285-amino acid polypeptide containing amino acid residues 26-310 of said polypeptide (i.e.,

"PAP II (1-285)") and which excludes the N-terminal twenty-five-amino acid signal sequence and analogs of PAP II (1-285) such as fragments and mutants (e.g., amino acid additions, deletions and substitutions) that substantially retain PAP II anti-viral and anti-fungal properties and exhibit reduced phytotoxicity compared to PAP. PAP II mutants are described in WO 99/60843, published December 2, 1999. Constructs, other intermediates and methods for preparing transgenic plants expressing these PAPs (as well as plant cells and protoplasts transfected with the PAP nucleic acids) are also described therein. These teachings are also applicable to L3. It is preferred to place the L3 and PAP nucleic acids under the control of separate regulatory units and polyadenylation sites.

L3 can be introduced and expressed in a variety of higher plants including monocots (e.g., cereal crops) and dicots in accordance with standard transformation techniques for the plant type of interest. See U.S. Patent 5,675,322 (and references cited therein), Horsch, *et al.*, Science 227:1229-1231 (1985); and Hartman, *et al.*, Bio/technology 12:919-923 (1994). Specific examples include maize, tomato, turfgrass, asparagus, papaya, sunflower, rye, beans, ginger, lotus, bamboo, potato, rice, peanut, barley, malt, wheat, alfalfa, soybean, oat, eggplant, squash, onion, broccoli, sugarcane, sugar beet, beets, apples, oranges, grapefruit, pear, plum, peach, pineapple, grape, rose, carnation, daisy, tulip, Douglas fir, cedar, white pine, scotch pine, spruce, peas, cotton, flax, canola, ornamentals and coffee.

Transgenic plants expressing L3 nucleic acid exhibit increased resistance to plant viruses, including but not limited to RNA viruses e.g., citrus tristeza virus, potexviruses such as (PVX, potato virus X), potyvirus (PVY), cucumber mosaic virus (CMV), tobacco mosaic viruses (TMV), barley yellow dwarf virus (BYDV), wheat streak mosaic virus, potato leaf roll virus (PLRV), plumpox virus, watermelon mosaic virus, zucchini yellow mosaic virus, papaya ringspot virus, beet western yellow virus, soybean dwarf virus, carrot read leaf virus and DNA plant viruses such as tomato yellow leaf curl virus. See also Lodge, *et al.*, PNAS USA 90:7089-7093 (1993); Tomlinson, *et al.*, J. Gen. Virol. 22:225-232 (1974); and Chen, *et al.*, Plant Pathol. 40:612-620 (1991).

Expression of L3 genes also provides increased resistance to diseases caused by plant fungi, including those caused by *Fusarium* (causing root rot of bean, dry rot of potatoes, head blight (scab) in wheat), *Pythium* (one of the causes of seed rot, seedling damping off and root rot), *Phytophthora* (the cause of late blight of potato and of root rots, and blights of many other plants), *Bremia*, *Peronospora*, *Plasmopara*, *Pseudoperonospora* and

Sclerospora (causing downy mildews), *Erysiphe graminis* (causing powdery mildew of cereals and grasses), *Verticillium* (causing vascular wilts of vegetables, flowers, crop plants and trees), *Rhizoctonia* (causing damping off disease of many plants and brown patch disease of turfgrasses), *Cochliobolus* (causing root and foot rot, and also blight of cereals and grasses), *Giberella* (causing seedling blight and foot or stalk rot of corn and small grains), *Gaeumannomyces* (causing the take-all and whiteheads disease of cereals), *Schlerotinia* (causing crown rots and blights of flowers and vegetables and dollar spot disease of turfgrasses), *Puccinia* (causing the stem rust of wheat and other small grains), *Ustilago* (causing corn smut), *Magnaporthae* (causing summer patch of turfgrasses), and *Schlerotium* (causing southern blight of turfgrasses). Other important fungal diseases include those caused by *Cercospora*, *Septoria*, *Mycosphaerella*, *Glomerella*, *Colletotrichum*, *Helminthosporium*, *Alternaria*, *Botrytis*, *Cladosporium* and *Aspergillus*.

Trichothecenes are a class of toxic, sesquiterpenoid secondary metabolites that are produced mainly by plant pathogenic fungi (Fernandez-Lobato *et al.*, Biochem. J. 267:709-713 (1990). Trichodermin is a member of this group of toxins. *Fusarium graminearum* and *F. culmorum* produce the trichothecene mycotoxin deoxynivalenol, which contaminates a substantial portion of agricultural crops such as wheat, barley and maize. Trichothecene resistance may be attained through a mutation in L3 e.g., *tcn1*, resulting in decreased fungal infection.

The L3 proteins of the present invention may also be introduced into other eukaryotic cells e.g., animal cells to reduce the cytotoxic effect of various pharmaceutical and therapeutic agents that contain single-chain RIPs. The cytotoxic effect of these RIPs is mediated by binding to endogenous L3 proteins in the cell. A preferred embodiment entails co-administration of a composition containing an L3 protein along with the RIP. The RIP may be administered in conjugated form to a ligand that recognizes a receptor on a target cell surface. By co-administration, it is meant administration of the L3 protein suitably prior to, simultaneously with or after the administration of the RIP such that the L3 will be present in the cell to reduce to cytotoxic effect of the RIP on various cells, particularly non-diseased cells. In more preferred embodiments, the L3 protein is a non-naturally occurring mutant as described herein.

Yet another use of the L3 proteins concerns the production of single chain RIPs such as PAP in prokaryotic cells such as *E. coli*. PAP, for example, is toxic to *E. coli*, particularly when expressed in high amounts. Co-administration or co-expression of an L3

protein in the prokaryote (e.g., bacterium) reduces the toxicity of the RIP and allows greater production of the recombinant RIP. By "co-expression" it is meant introducing an exogenous nucleic acid encoding an L3 protein of the present invention into the prokaryotic cell along with the nucleic acid encoding the RIP. Regardless of the manner in which the cell is treated so as to contain the L3 protein, what is important is that the L3 protein is present in the cell when PAP is produced so as to reduce the cytotoxicity of the RIP. While not intending to be bound by theory, Applicants believe that because L3 is highly conserved between prokaryotes and eukaryotes, the RIP binds endogenous L3 protein in the prokaryote.

The invention will be further described by reference to the following detailed examples. These examples are provided for purposes of illustration only and are not intended to be limiting as to the scope of the invention described herein, unless otherwise specified.

EXAMPLE 1

Pokeweed antiviral protein accesses ribosomes by binding to L3.

Pokeweed antiviral protein (PAP), a 29 kDa ribosome-inactivating protein (RIP), catalytically removes an adenine residue from the conserved a-sarcin loop of the large rRNA, thereby preventing the binding of eEF-2/GTP complex during protein elongation. Since the a-sarcin loop has been placed near the peptidyl transferase center in *E. coli* ribosomes, we investigated the effects of alterations at the peptidyl transferase center on the activity of PAP. We demonstrate here that a chromosomal mutant of yeast, harboring the mak8-1 allele of peptidyl transferase-linked ribosomal protein L3 (RPL3), is resistant to the cytostatic effects of PAP. Unlike wild-type yeast, ribosomes from mak8-1 cells are not depurinated when PAP expression is induced *in vivo*, indicating that wild-type L3 is required for ribosome depurination. Co-immunoprecipitation studies show that PAP binds directly to L3 or Mak8-1p *in vitro*, but does not physically interact with ribosome associated Mak8-1p. L3 is required for PAP to bind to ribosomes and depurate the 25S rRNA, suggesting that it is located in close proximity to the a-sarcin loop. These results demonstrate for the first time that a ribosomal protein provides a receptor site for an RIP and allows depurination of the target adenine.

The abbreviations used are as follows: PAP, pokeweed antiviral protein; RIP, ribosomal inactivating protein; eEF-2, eukaryotic elongation factor 2.

EXPERIMENTAL PROCEDURES

Yeast strains and vectors. The cDNAs encoding PAP (NT188) and PAPx (NT224) were introduced as SmaI/BglII fragments into the yeast expression vector YEp351. PAPx is an active site mutant of PAP with a point mutation (E176V), which abolishes enzymatic activity. Hur, *et al.*, Proc. Natl. Acad. Sci. US 92:8448-8452 (1995). Transcription of the cDNAs was under the control of a galactose-inducible GAL1 promoter. Vectors containing PAP or PAPx were transformed (Ito, *et al.*, J. Bacteriol. 153:163-168 (1983)) into the yeast strains *S. cerevisiae* W303 (MAT α , ade2-1 trp1-1 ura3-1 leu2-3, 112 his3-11, 15can1-100), 1906 (MAT α , leu2 mak8-1), or the isogenic strains JD980 (MAT α lys2 his3 ura3 leu2 Δ trp1 Δ RPL3 Δ ::hisG), containing either pRPL3 or pmak8-1 (as described in Example 2, now Peltz, *et al.*, Mol. Cell. Biol. 19(1):384-391 (1999)). YEp351 transformed into all cell types was used as a negative control.

Yeast growth and time course induction. Yeast cells were grown in 300 ml of H-Leu medium (See, Treco, *et al.*, Current Protocols in Molecular Biology, Ausubel, *et al.*, eds. Wiley (1993)); with 2% raffinose at 30 °C to an A₆₀₀ = 0.6. Aliquot for protein analysis (2 ml), RNA extraction (15 ml) and ribosome isolation (25ml) were removed and pelleted by centrifugation at 2,000 x g for 5 min. The remaining culture was pelleted at the same speed, washed in H-Leu medium and resuspended in H-Leu medium with 2% galactose to induce the expression of PAP and PAPx. At various times during induction (2, 4, 8, 12 and 24 h), aliquot were removed, pelleted and stored at -80 °C. Pellets for ribosome isolation were washed twice in water and quickly frozen in liquid N₂.

Ribonuclease protection assay. RNA from frozen yeast aliquot was extracted according to Cui *et al.*, EMBO J. 15:5726-5736 (1996). Total RNA from the time point aliquot of PAP and PAPx induced in mak8-1 cells was used in the RNase protection assay as described in Tumer, *et al.*, J. Virol. 72:1036-1042 (1998).

Protein expression analysis. Frozen pellets of 2 ml aliquot of cells harvested during the time course induction of PAP and PAPx were resuspended in an equal volume of cold (4 °C) phosphate buffered saline (PBS) buffer and 0.3 g of 0.5 mm diameter glass beads. Cells were vortexed for 2 min and centrifuged at 16,000 x g for 5 min. Supernatant total protein was quantified by Bradford using BSA as a standard. Total protein (30 μ g) from each time point was separated through 12% SDS-PAGE, transferred to nitrocellulose, and probed with either an affinity purified (Lindstrom, *et al.*, Plant Physiol. 106:7-16 (1994)) polyclonal antibody to PAP (1:5000) or a monoclonal antibody to L3 (anti TCM

7.1.1, gift of J.R. Warner) (1:5000). PAP and L3 were visualized by chemiluminescence using a Renaissance kit (NEN, Du Pont). To probe proteins with two separate antibodies, blots were stripped by incubation in 8M guanidine hydrochloride at room temperature for 30 min. The nitrocellulose was washed four times in PBST for 15 min each before exposing the blot to another antibody.

Isolation of yeast ribosomes.

Yeast cells harvested from 25 ml aliquot during the time course induction of PAP and PAPx in wild-type and mak8-1 cells were ground to a fine powder in liquid N₂ with a mortar and pestle. Cold (4 °C) buffer A [4 ml of 200 mM Tris-HCl pH 9.0, 200 mM KCl, 200 mM sucrose, 25 mM MgCl₂, 25 mM EGTA, 25 mM 2-mercaptoethanol] was added to the yeast powder and centrifuged at 16,000 x g for 20 min. The resulting supernatant was increased to 13 ml with buffer A and layered over a 10 ml cushion of 1 M sucrose, 25 mM Tris-HCl pH 7.6, 25 mM KCl, 5 mM MgCl₂. Ribosomes were pelleted by centrifugation at 311,000 x g for 3.5 h at 4 °C. The pellets were resuspended in 100 µl of 25 mM Tris-HCl pH 7.6, 25 mM KCl, 5 mM MgCl₂, aliquoted and stored at -80 °C.

rRNA depurination assay.

Total ribosomes (50 µg) isolated from yeast cells expressing PAP, PAPx or vector control were resuspended in RIP buffer [167mM KCl, 100 mM Tris-HCl pH 7.2, 100 mM MgCl₂] to a final volume of 100 µl. Extraction of rRNA and subsequent analysis for depurination were conducted according to Turner, *et al.*, Proc. Natl. Acad. Sci. USA 94:3866-3871 (1997). A positive control standard for depurination was generated by incubating 50 µg of ribosomes from wild-type yeast with 100 ng of purified PAP (Calbiochem) in RIP buffer. The mixture was incubated at 37°C for 30 min and RNA isolated as referenced above. Depurination of rRNA was confirmed by the presence of a 360 nt fragment visible on the urea-acrylamide gel.

Co-immunoprecipitation.

PAP and L3 expressed *in vivo* in wild-type and mak8-1 cells were co-immunoprecipitated with the monoclonal antibody to L3 essentially as described in Otto, *et al.*, Meth. Cell Biol. 37:119-126 (1993). Ribosomes (100 µg) from cells induced to express PAP, PAPx or vector control were used as substrate for immunoprecipitation with protein A-Sepharose beads. The pelleted complex of antibody and protein was eluted from the beads with SDS sample buffer and visualized by immunoblot analysis using the antibodies to PAP and L3. Co-immunoprecipitation of *in vitro* synthesized L3 with purified PAP was

used to demonstrate a direct interaction between these two proteins. Radiolabeled L3 (3 nM), synthesized by a linked transcription translation system (TNT Coupled Reticulocyte Lysate System (Promega)) was incubated with 3 nM purified non-radiolabeled PAP and immunoprecipitated with the monoclonal L3 antibody. Proteins were eluted from the
5 Sepharose beads with SDS sample buffer and the solution divided in half. Half was separated through 12% SDS-PAGE, transferred to nitrocellulose and probed with the polyclonal antibody to PAP. The remaining half was also separated through 12% SDS-PAGE, then incubated with Entensify Solution A and B (NEN, Du Pont), dried and exposed to autoradiography.

10 RESULTS

Mak8-1 cells are resistant to PAP.

PAP removes a specific adenine residue from the α -sarcin loop of yeast 25S rRNA. Since this loop is located near the peptidyltransferase center, PAP was introduced into the strain harboring the mak8-1 allele to determine if this mutation conferred resistance
15 to the cytostatic effects of PAP. Both wild type and mak8-1 cells were transformed with the LEU2-based vector, pNT188, containing the PAP cDNA under the control of a GAL1 promoter. Galactose induction of PAP expression did not have a cytostatic effect on the growth of the strain harboring the mak8-1 allele (photograph not shown). In contrast, growth of wild-type cells was significantly inhibited when PAP expression was induced by
20 galactose. To confirm this observation, isogenic RPL3::hisG strains (Peltz, *et al.*, *infra*) were tested for their sensitivity to PAP. Cells harboring pmak8-1 were able to grow under PAP induction, whereas cells containing pRPL3 encoding wild type L3 did not grow (data not shown).

PAP is expressed in mak8-1 cells. Resistance to PAP may have arisen
25 because either transcript or protein had not accumulated in mak8-1 cells. To determine if PAP transcripts were synthesized, nuclease protection assays were performed to examine the accumulation of PAP mRNA relative to CYH2 mRNA, an internal control which encodes the ribosomal protein L29 (Stocklein, *et al.*, *Curr. Genet.* 1:177-183)). The levels of PAP transcript were compared to those of PAPx, the active site mutant of PAP. The zero
30 hour time point represents cells grown in raffinose under non-inducing conditions. Cells grown in raffinose did not express PAP or PAPx transcripts (photograph not shown). However, two hours after shifting to galactose-containing medium, transcripts corresponding to both PAP and PAPx were detected in mak8-1 cells. Quantitation of PAP

mRNA, relative to the CYH2 internal control, indicated that both PAP and PAPx transcript levels remained constant during the time course of induction. A protected RNA fragment corresponding to PAP was not observed in cells containing the vector alone, eight hours after induction by galactose (photograph not shown). When tRNA was used in place of total cellular RNA as a control, no specific binding by the radiolabeled probes was detected (photograph not shown). These results demonstrated that both PAP and PAPx mRNAs were transcribed in cells harboring the mak8-1 allele and no significant difference in the level of transcripts could be detected in cells expressing PAP or PAPx.

To test whether PAP was expressed and accumulated in mak8-1 cells, immunoblot analysis was conducted on aliquots harvested from cells grown on galactose medium through a 24 hour time course. The same experiment was carried out with wild-type yeast cells harboring PAP (NT188) and PAPx (NT224). Similar amounts of PAP and PAPx were expressed in mak8-1 cells, suggesting a lack of toxicity due to PAP accumulation, whereas in wild type cells, PAPx was expressed to a greater degree than PAP (photograph not shown). The higher molecular mass protein reacting with the PAP antibody likely represents the precursor form of PAP, observed previously in yeast (Hur, *et al, supra*). Over-expression of PAPx often results in lower molecular mass proteins, most likely breakdown products, seen clearly in wild-type cells induced for 24 h. However, the primary band in each immunoblot is the 29 kDa mature form of PAP.

Mak8-1 ribosomes are not depurinated by PAP.

To determine whether there were differences between the ability of PAP to depurinate ribosomes from wild-type and mak8-1 cells *in vivo*, ribosomes were isolated from yeast cells induced to express PAP or PAPx for 8 hours. rRNA was isolated from these ribosomes, treated with aniline and separated on a urea-acrylamide gel. Depurination of rRNA was revealed by the presence of the 360-nucleotide (nt) fragment produced by removal of a purine residue from the 25S rRNA and subsequent cleavage at that site by treatment with aniline. A positive standard for depurination was generated by incubating wild-type ribosomes with PAP *in vitro*, extracting the rRNA and treating it with aniline (photograph not shown). Ribosomes isolated from wild-type cells harvested 8 hours after induction of PAP expression were depurinated, whereas ribosomes of cells harboring the mak8-1 allele were not depurinated during PAP expression *in vivo* (photograph not shown). Ribosomes isolated from both cell types expressing PAPx were not depurinated, which was consistent with the prior observation that PAPx lacks enzymatic activity.

PAP does not associate with ribosomes in mak8-1 cells.

A possible reason for the lack of depurination of rRNA in mak8-1 cells was that PAP might not be able to access its rRNA substrate in these cells. To determine if PAP associated with ribosomes in wild-type cells, ribosomes examined for depurination were also assessed by immunoblot analysis with the affinity-purified antibody against PAP. Both PAP and PAPx were associated with ribosomes in wild-type cells (photograph not shown). In contrast, neither PAP nor PAPx could be detected with ribosomes isolated from mak8-1 cells. The higher levels of PAPx associated with ribosomes of wild-type cells likely reflected the increased level of expression of enzymatically inactive PAPx relative to the enzymatically active PAP (photograph not shown). The immunoblots of ribosomal proteins were stripped and re-probed with a monoclonal antibody against L3 to illustrate that L3 or its mutant form were detected on both types of ribosomes and that similar amounts of protein were loaded from both cell types (photograph not shown).

PAP binds free L3 and Mak8-1p.

Results described above indicated that PAP is associated with ribosomes in wild-type cells, but not in mak8-1 cells, suggesting that PAP may interact with L3. To test the hypothesis of direct interaction with L3, purified PAP was mixed with *in vitro* synthesized L3 or Mak8-1p and co-immunoprecipitated with the monoclonal L3 antibody. Purified PAP co-immunoprecipitated with L3 or Mak8-1p when it was mixed with either protein and not when it was incubated alone (photograph not shown). As expected, L3 and Mak8-1p were immunoprecipitated with L3 antibody when they were each mixed with PAP or incubated alone (photograph not shown). These results indicate that PAP binds directly to L3 or Mak8-1p in its free form (photograph not shown).

Co-immunoprecipitation of PAP and L3 from ribosomes.

To determine if PAP interacts with L3 and Mak8-1p incorporated into ribosomes, ribosomes from wild-type or mak8-1 cells expressing either PAP, PAPx or vector alone were immunoprecipitated with the monoclonal L3 antibody. PAPx was co-immunoprecipitated with L3 from ribosomes of wild-type but not mak8-1 cells indicating that PAPx does not interact with the mutant form of L3 in ribosomes (photograph not shown). The lack of co-immunoprecipitation of PAP with L3 from ribosomes of wild-type cells may reflect the previous observation that wild-type protein is not synthesized as abundantly as the active site mutant (photograph not shown). The difference may also be the result of variation in the kinetics of association between PAP and PAPx, namely PAP may

dissociate more readily from its substrate, the ribosomes, than PAPx. The results demonstrate that L3 or Mak8-1p was immunoprecipitated from ribosomes of both cell types and that similar amounts of protein were loaded on the gel. These results suggest that the absence of association between PAP and Mak8-1p in ribosomes may be the result of a conformational change, such that the peptide sequence or tertiary structure required is not accessible when Mak8-1p is incorporated into ribosomes. The lack of co-immunoprecipitation of PAP with Mak8-1p in ribosomes substantiates earlier results that showed absence of PAP in ribosomes from mak8-1 cells and lack of rRNA depurination.

A previous report is that *in vivo* induction of PAP expression in yeast had a cytostatic effect (Hur, *et al.*, *supra*). The work described herein demonstrates that cells containing the mak8-1 allele are resistant to PAP. The lack of growth inhibition observed in mak8-1 cells is believed to be due to the fact that ribosomes from these cells are not associated with PAP, and consequently are not depurinated. The observation that PAP expressed in wild-type yeast depurinates ribosomes, but does not when expressed in mak8-1 cells, indicates that wild-type L3 is required for depurination of ribosomes. Co-immunoprecipitation experiments with isolated proteins illustrates that PAP directly binds to L3 and Mak8-1p *in vitro*. However, when the experiments were repeated using intact ribosomes, PAP co-immunoprecipitated only with wild-type L3 from ribosomes and not with Mak8-1p, indicating that PAP does not interact with Mak8-1p in ribosomes. The quaternary structure of a ribosome containing Mak8-1p may differ from a wild-type ribosome, such that the binding site for PAP may be masked in the mutant ribosomes. Alternatively, a difference in post-translational modifications between L3 and Mak8-1p may affect its interaction with PAP *in vivo*. The hypothesis for altered binding by the mutant L3 is supported by the observation that neither PAP nor PAPx was detected in association with ribosomes in mak8-1 cells even though both proteins were associated with ribosomes in wild-type cells.

This evidence demonstrates a link between L3 and the a-sarcin loop in eukaryotic ribosomes. Experiments designed to reconstitute the minimal ribosomal particle still capable of enzyme activity have established that L3 is essential for maintaining peptidyltransferase activity (Hampl, *et al.*, J. Biol. Chem. 256:2284-2288 (1981)). A photolabile cDNA probe targeted to the central loop of domain V was shown to cross-link to L3 (Alexander, *et al.*, Biochem. 33:12109-12118 (1994)). With the use of a photolabile oligodeoxynucleotide probe complementary to the a-sarcin region of *E. coli*, Muralikrishna,

et al., (Nucleic Acids Res. 25:4562-4569 (1997)) recently demonstrated the proximity of the a-sarcin region to domains IV and V of *E. coli* rRNA. tRNA localization experiments further demonstrated the mutual proximity of domains IV, V and VI within the 50S subunit (Joseph, *et al.*, EMBO J. 15:910-916 (1996)). Chemical and enzymatic footprinting have shown that L3 binds in region VIA of 23S rRNA near the a-sarcin loop (Muralikrishna, *et al.*, Biochem. 30:5421-5428 (1991)). The results described herein substantiate prior data (not shown) that both PAP and PAPx bind to the a-sarcin loop because they suggest that L3 is in close proximity of the a-sarcin loop in yeast 25SrRNA.

These data lead us to propose a model to explain the interaction between PAP and L3. Co immunoprecipitation studies demonstrate that PAP binding to ribosomes requires wild-type L3. Therefore, we suggest that PAP accesses its substrate, the a-sarcin loop, by recognizing and binding to L3. Once bound, the close proximity of L3 to the a-sarcin loop facilitates the subsequent depurination of the 25S rRNA by PAP. Since PAPx does not interact with ribosomes from mak8-1 cells, we contend that the PAP binding site may be masked in mak8-1 ribosomes. The mak8-1 gene product encodes a mutant L3 that differs from the wild-type by only two amino acid substitutions, W255C and P257S, which may be sufficient to alter the shape of the protein product (Peltz, *et al.*, *infra*), affecting its interaction with other components of the ribosome. If rRNA is necessary to place the ribosomal proteins in a proper conformation to facilitate PAP binding, the point mutations in Mak8-1p may alter the interaction between rRNA and Mak8-1p.

While the mechanism underlying the catalytic activity of RIPs is understood, very little is known about how RIPs gain access to the ribosome. Although all RIPs have the same specificity for adenine 4324 of naked 28S rRNA, they show very different levels of activity against ribosomes of different species. For example, ricin is 23,000 times more active on rat liver ribosomes than on plant ribosomes (Harley, *et al.*, Proc. Natl. Acad. Sci. USA 79:5935-5938 (1982)), while PAP is equally active on ribosomes from all five kingdoms. These data suggest that the differences in sensitivity of ribosomes to RIPs may reflect differences in interactions of RIPs with ribosomal proteins. Endo and Tsurugi (Endo, *et al.*, J. Biol. Chem. 263:8735-8739 (1988)) showed that the ricin A-chain depurinated rat rRNA at adenine 4324 in intact ribosomes much more efficiently than naked 28S rRNA. Conversely, the ricin A-chain depurinated naked 23S rRNA of *E. coli* at the homologous adenine 2660, and did not depurinate intact *E. coli* ribosomes. Formation of a covalent complex between saporin and a component of the 60S subunit of yeast ribosomes

was shown by chemical cross-linking (Ippoliti, *et al.*, FEBS Lett. 298:145-148 (1992)). Similarly, the ricin A-chain has been cross-linked to mammalian ribosomal proteins L9 and L10e (Vater, *et al.*, J. Biol. Chem. 270:12933-12940 (1995)). Despite some evidence for the dependence of RIP activity on the type of ribosomal substrate, the functional significance of the association between RIPs and ribosomal proteins has not been reported. Nevertheless, these observations support the hypothesis for a molecular recognition mechanism involving one or more ribosomal proteins that could provide receptor sites for toxins and favor optimal binding to the target adenine. The results reported here demonstrate that PAP gains access to the ribosome by recognizing L3. Since L3 is highly conserved among ribosomes from different species, the interaction between PAP and L3 may be the underlying reason for the broad-spectrum activity of PAP on ribosomes from different organisms.

The text of Example 1 is contained in Hudak, *et al.*, J. Biol. Chem. 274:3859-3864 (1999).

EXAMPLE 2

Ribosomal protein L3 mutants alter translational fidelity and promote rapid loss of the yeast killer virus.

Programmed -1 ribosomal frameshifting is utilized by a number of RNA viruses as a means to ensure the correct ratio of viral structural to enzymatic proteins available for viral particle assembly. Altering frameshifting efficiencies upsets this ratio, interfering with virus propagation. We have previously demonstrated that compounds that alter the kinetics of the peptidyl-transfer reaction affect programmed -1 ribosomal frameshift efficiencies and interfere with viral propagation in yeast. Here, the use of a genetic approach lends further support to the hypothesis that alterations affecting the ribosome's peptidyl-transferase activity lead to changes in frameshifting efficiency and virus loss. Mutations in the *RPL3* gene, which encodes a ribosomal protein located at the peptidyl-transferase center, promote approximately 3- to 4-fold increases in programmed -1 ribosomal frameshift efficiencies and loss of the M₁ killer virus of yeast. The *mak8-1* allele of *RPL3* contains two adjacent missense mutations which are predicted to structurally alter the Mak8-1p. These results support the hypothesis that alterations in the peptidyl-transferase center affect programmed -1 ribosomal frameshifting.

INTRODUCTION

Programmed -1 ribosomal frameshifting is a mode of regulating gene expression used predominantly by RNA viruses and by a subset of bacterial genes to induce elongating ribosomes to shift reading frame in response to specific mRNA signals (reviewed in 16,24,27,30). Many viruses of clinical, veterinary and agricultural importance utilize programmed frameshifting for the production of their structural and enzymatic gene products (reviewed in 5,6,24,27,30,51). Thus, ribosomal frameshifting is a unique target to identify and develop antiviral agents (20,41). Programmed -1 ribosomal frameshifting causes the ribosome to slip one base in the 5' direction and requires two *cis*-acting mRNA signals. The first sequence element is called the 'slippery site' which, in eukaryotic viruses, consists of a heptamer sequence spanning three amino acid codons X XXY YYZ (the *gag* reading frame is indicated by spaces), where XXX can be any three identical nucleotides, YYY can be AAA or UUU, and Z is A, U, or C (8,17,21,31). The second frameshift-promoting signal is usually a sequence that forms a defined RNA secondary structure, such as an RNA pseudoknot (7,17,36).

A 'simultaneous slippage model' has been proposed to explain how ribosomes can be induced to change reading frames (31). A translating ribosome in which the A- and P-sites are occupied by tRNAs is forced to pause over the slippery site as a consequence of the RNA pseudoknot. The increased pause time over this sequence is thought to give an opportunity for the ribosome and bound tRNAs to slip one base in the 5' direction. Because of the nature of the slippery site, this still leaves their non-wobble bases correctly paired with the mRNA in the new reading frame. Following the slip in the -1 direction, the ribosome continues translation in the new reading frame, producing the Gag-pol polyprotein.

In the yeast *Saccharomyces cerevisiae* the L-A dsRNA virus utilizes a -1 ribosomal frameshift event for the production of a Gag-Pol fusion protein and has been an excellent model system to investigate this process (reviewed in 12,20). M₁, a satellite dsRNA virus of L-A that encodes a secreted killer toxin, is encapsidated and replicated using the Gag and Gag-pol gene products synthesized by the L-A virus (reviewed in 58). Maintaining the appropriate ratio of Gag to Gag-Pol is critical for maintenance of the M₁ virus (21). Alteration of the frameshift process by as little as 2- to 3-fold promotes rapid loss of M₁ (21,22). Compounds that bind to the peptidyl transferase center on the ribosome and reduce translation fidelity can also modulate ribosomal frameshifting (19). Anisomycin

and sparsomycin were shown to alter programmed -1 ribosomal frameshifting efficiencies both in cells and in *in vitro* translation extracts and to promote loss of the yeast L-A and its satellite dsRNA virus, M₁ (19). These results indicate that modulating the ribosomal peptidyl transferase center can alter the efficiency of programmed -1 ribosomal frameshifting and lead to inefficient virus propagation.

In the current study we have genetically investigated the role of a ribosomal protein that is located at the ribosomal peptidyl transfer center in modulating programmed frameshifting efficiencies. Previous results have shown that the yeast *RPL3* gene encoding the ribosomal protein L3 participates in the formation of the peptidyl transferase center (reviewed in 38,39). Mutations in the *RPL3* gene (called *TCM1*) were initially identified by conferring resistance to the peptidyl-transferase inhibitors trichodermin and anisomycin (32,45). Independently, the *MAK8* gene (*MAK* = *MA*intenance of *K*iller) was identified by the inability of mutant alleles to maintain the M₁ satellite virus (59). Subsequent analysis demonstrated that *MAK8* is allelic to *RPL3* (60). Thus, a mutation in a ribosomal protein located in the peptidyl-transferase center that cannot maintain the killer virus has been identified. We hypothesized that the underlying cause of killer virus loss observed in these cells may be a consequence of increased programmed -1 ribosomal frameshifting efficiency, i.e. that the *mak8* alleles may demonstrate a Mof phenotype. The results presented here demonstrate that strains harboring the *mak8-1* allele have increased programmed frameshifting efficiencies and strongly suggest that the loss of the killer virus is a due to alteration in translation fidelity. These results support the notion that modulating the peptidyl-transferase center results in alteration of programmed -1 ribosomal frameshifting efficiencies, promoting loss of the killer virus.

Materials and Methods

Strains, media, enzymes, oligonucleotides, and drugs.

E. coli DH5 α and MV1190 were used to amplify plasmid DNA. The yeast strains used in this study are listed in Table 1. Transformation of yeast and *E. coli* were performed as described previously (13). YPAD, YPG, SD, synthetic complete medium (H-) and 4.7 MB plates for testing the killer phenotype were as previously reported (22). Restriction enzymes were obtained from Promega, MBI Fermentas, BRL and Boehringer Mannheim. T4 DNA ligase and T4 DNA polymerase were obtained from Boehringer Mannheim, and precision *Taq* polymerase was obtained from Stratagene. Radioactive nucleotides were obtained from NEN. Oligonucleotides used in these studies were purchased from IDT, and DNA sequence analysis was performed by the UMDNJ-RWJ DNA synthesis center. Anisomycin was purchased from Sigma, and sparsomycin was a generous gift from Dr. S. Pestka.

Plasmid constructs and programmed ribosomal frameshift assays.

BlueScript KS plasmid was obtained from Strategene. The pRS series of plasmids (10,47) and pAS134 (1) have been previously described. Full length *RPL3* and *mak8-1* were amplified from genomic DNA by polymerase chain reaction using the oligonucleotide primers -300 *Kpn* I (5' CCCCAGGTACCTCACGCACACTGGAATGAAT 3') and +1300 *Sac* I (5' CCCCAGAGCGCAACCTCCATTTGGACTTGG 3'), and were cloned into the pRS300 series (pRS314, pRS315 and pRS316) digested with *Kpn* I and *Sac* I to make the pRPL3 and the pmak8-1 series of plasmids. To construct a *RPL3* gene disruption plasmid, the *Kpn* I/*Sac* I *RPL3* clone was subcloned into BlueScript KS (KS-RPL3), digested with *Sph* I, the overhanging ends were filled with dNTPs using T4 DNA polymerase, and was then digested with *Xba* I. Subsequently, pAS134 was digested with *Xba* I and *Pvu* II to liberate the *hisG-URA3* cassette which was subcloned into the *Xba* I/blunt ended KS-RPL3 to create pJD168.

Plasmids to monitor programmed ribosomal frameshifting were previously described (11,12,18,19,54). Briefly, in all of these plasmids, transcription is driven from the yeast *PGK1* promoter into an AUG translational start site. The *E. coli lacZ* gene serves as the reporter, and transcription termination utilizes the yeast *PGK1* transcriptional terminator. In the p0 plasmids, *lacZ* is in the 0-frame with respect to the translational start site, and measurement of β -galactosidase activity generated from cells transformed with

these plasmids serve as the 0-frame controls. In the p-1 series, *lacZ* is in the -1 frame with respect to the translational start site, and is 3' of the L-A-programmed -1 ribosomal frameshift signal such that β -galactosidase can only be produced as a consequence of a programmed -1 ribosomal frameshift. Similarly, in the p+1 series, *lacZ* is in the +1 frame with respect to the translational start site, and is 3' of the Ty1-programmed +1 ribosomal frameshift signal such that β -galactosidase can only be produced as a consequence of a programmed +1 ribosomal frameshift. The efficiency of programmed ribosomal frameshifting is calculated by determining the ratio of β -galactosidase activity produced by cells harboring either p-1 or p+1 divided by the beta-galactosidase activity produced by cells harboring p0, and multiplying by 100%. Measurement of programmed -1 ribosomal frameshifting in the presence of anisomycin and sparsomycin were as described (19).

Construction of isogenic *mak8-1* and *RPL3* strains.

Yeast strains JD100 and JD973 were mated, the diploids transformed with *Pvu* II-linearized pJD168, and selected on H-Ura medium (22). Disruption of the *RPL3* locus on one chromosome was confirmed by Southern analysis as described below. Diploids were selected for loss of the chromosomal *URA3* insert by growth on 5-fluoroorotic acid (5-FOA). Ura-cells were transformed with pRPL3-Ura3, sporulated, and dissected onto YPAD medium. The resulting tetrads are from cross JD980. *rpl3Δ* status was confirmed by the inability of spore clones to grow in the presence of 5-FOA. To construct isogenic *mak8-1* strains, cells were transformed with pmak8-1-TRP1, and were subsequently grown in the presence of 5-FOA to select for loss of the wild-type pRPL3-Ura3 plasmid.

Killer Assay

The killer virus assay was carried out as previously described (21). Briefly, yeast colonies were replica plated to 4.7MB plates (22) with a newly seeded lawn of strain 5x47 (0.5 ml of a suspension at 1 unit of optical density at 550 nm per ml per plate). After 2-3 days at 20°C, killer activity was observed as a clear zone around the killer colonies. Loss-of-killer assays were performed in multiple wild-type and mutant strains.

Nucleic acids analyses

DsRNAs of L-A and *M₁* viruses were prepared as described (25), separated by electrophoresis through 1.2% agarose gels, denatured in the gels in two changes of 30 min each of 50% formamide, 9.25% formaldehyde-1 X Tris-acetate-EDTA at room temperature and transferred to nitrocellulose in 20X SSC. L-A and *M₁* (-) strand RNA

probes were labeled with [α - 32 P]UTP and hybridized to blots and washed as described in (22). RNase protection assays to determine the relative abundances of the *lacZ* -1 frameshift reporter mRNAs and U3 small nuclear RNA (snRNA) in isogenic wild-type, *mak8-1* and *L3Δ* strains were carried out as described (44).

5

Results

The *mak8-1* allele of *RPL3* promotes increased programmed -1 ribosomal frameshifting efficiencies.

Previous studies have demonstrated that peptidyl-transferase inhibitors specifically affect programmed -1 ribosomal frameshifting efficiencies (19). Thus, we predicted that yeast strains harboring chromosomal mutations affecting the peptidyl-transferase center would also have defects in programmed -1 ribosomal frameshifting and killer virus maintenance. The *mak8-1* allele of ribosomal protein L3 initially presents a logical candidate to test this hypothesis, since strains harboring this mutation promoted loss of the killer virus. Programmed ribosomal frameshifting efficiencies were measured *in vivo* using a series of *lacZ* reporter plasmids as described previously (12,17,19,54). The efficiencies of -1 and +1 ribosomal frameshifting are calculated by determining the ratio of beta-gal activities measured in cells harboring p-1 or p+1 to those harboring p0, and multiplying by 100%.

After cells (strain 1906; Table 1) harboring the *mak8-1* allele were transformed with p0, p-1, or p+1 the efficiencies of programmed ribosomal frameshifting were determined. The results demonstrated that the programmed -1 frameshifting efficiency in the *mak8-1* strain was 5.2%, approximately 3-fold greater than the 1.7% - 2.0% normally observed in wild-type strains (Table 2). To confirm that the change in programmed -1 ribosomal frameshifting efficiency was solely due to the *mak8-1* allele, isogenic wild-type and *mak8-1* strains were constructed and programmed -1 frameshifting was determined in these cells as described above (cross JD980; Table 1). In isogenic backgrounds, the *mak8-1* allele of *RPL3* promotes an approximately 2.5-fold increase in programmed -1 ribosomal frameshift efficiency ($\approx 4.9\%$ in *mak8-1* compared to $\approx 1.9\%$ in the isogenic wild-type strain; Table 2). The *mak8-1* allele was also unable to maintain the M₁ killer virus (Table 2). However, *mak8-1* had no effect on programmed +1 ribosomal frameshifting (Table 2). Taken together, these results demonstrate that the *mak8-1* allele causes an alteration in programmed -1 ribosomal frameshift efficiencies. Thus, the *mak8-1*

30

allele is also a *mof* mutant, in that these strains demonstrate increased programmed -1 ribosomal frameshifting efficiencies and loss of the killer virus (11,12).

Characterization of the *mak8-1* lesion.

The *mak8-1* allele was amplified by PCR from genomic DNA harvested from strain 1906 and the DNA sequence was obtained from three independently isolated clones (see Materials and Methods). The results demonstrated that the *mak8-1* allele harbors two separate mutations spaced four nucleotides apart. The G765C mutation encodes a Trp-to-Cys change at amino acid residue 255. The C769T mutation changes a proline at residue 257 to serine, a potentially significant structural change.

Strains harboring the *mak8-1* allele are resistant to the effects of peptidyl-transferase inhibitors on programmed -1 ribosomal frameshifting.

We previously demonstrated that peptidyl-transferase inhibitors specifically alter programmed -1 ribosomal frameshifting efficiencies (19). It has been previously demonstrated that cells harboring mutant alleles of *rpl3* are resistant to the cytotoxic effects of peptidyl-transferase inhibitors (28,32,45,60). These include strains harboring the *mak8* and the *tcm1* classes of *RPL3* alleles. Thus, we asked whether this class of agents affect programmed -1 ribosomal frameshifting in strains harboring the *mak8-1*. To examine this, *mak8-1* and wild-type cells harboring either p0 or p-1 frameshift indicator plasmids were grown in the presence of various concentrations of either anisomycin or sparsomycin for four hours and programmed ribosomal frameshifting efficiencies were determined as described above. The results demonstrated that both anisomycin and sparsomycin altered ribosomal frameshifting in wild-type cells (Figures not shown). In contrast, neither anisomycin nor sparsomycin had any further effect on programmed -1 ribosomal frameshifting in *mak8-1* strains (Figures not shown). These results provide strong evidence that a defect affecting the peptidyl-transferase center is responsible for the observed increase in programmed -1 ribosomal frameshifting in *mak8-1* cells.

Discussion

Mutations affecting ribosomal protein L3 promote loss of the M₁ killer virus by altering the efficiency of programmed -1 ribosomal frameshifting.

The mechanism governing programmed -1 ribosomal frameshifting suggests that drugs and mutations which affect the peptidyl-transfer reaction may alter programmed -1 ribosomal frameshift efficiencies and have antiviral effects (19). We previously used

peptidyl-transferase inhibitors to demonstrate the validity of this model (19). The results presented here have shown that an allele encoding a mutant form of ribosomal protein L3, which was previously implicated in formation of the peptidyl-transferase center, also alters programmed -1 ribosomal frameshift efficiencies and has antiviral effects. These results support the hypothesis that the peptidyl-transferase center may present a novel target for anti-retroviral therapeutic agents.

It has long been known that cells harboring *mak8* alleles cannot propagate the M₁ satellite virus (59). Additional alleles of *RPL3*, named *tcm1*, were also characterized based on their resistance to the peptidyl-transferase inhibitor trichodermin (26,28,32,45,46). These alleles also have the Mak⁻ phenotype (60). However, the precise mechanism responsible for killer virus loss in this class of mutants was not determined. The results presented here demonstrate that alterations in programmed -1 ribosomal frameshifting efficiencies are responsible for the inability cells harboring this mutation to maintain the M₁ dsRNA virus. Given the previous demonstration that peptidyl-transferase inhibitors promote virus loss by altering programmed -1 ribosomal frameshift efficiencies, as well as the role of the L3 protein in peptidyl-transferase center formation, our results indicating that mutations in *RPL3* affect programmed -1 ribosomal frameshifting are consistent with the view that altering peptidyl transfer activity affects this process.

We envision two models to explain the role of the L3 protein in programmed -1 ribosomal frameshifting. In one, we suggest that the incorporation of defective L3 protein (Mak8-1p) into ribosomes would result in suboptimal L3 function, yielding the observed translational fidelity defect. Alternatively, it is possible that expression of this allele results in a subpopulation of L3-deficient ribosomes. Since it is thought that the large rRNA is responsible for peptidyl-transferase activity (38,61), these L3-deficient ribosomes would retain a small amount of peptidyl-transferase activity. In both scenarios, defects in peptidyl-transferase activity are predicted to slow the rate of translation elongation while both the ribosomal A- and P-sites are occupied. In the context of frameshifting, this would result in a longer ribosomal pause at the programmed -1 ribosomal frameshift signal, increasing the likelihood of a successful frameshift. If this model is true, then the observed increases in programmed -1 ribosomal frameshifting efficiencies promoted by these alleles should represent the sum of programmed frameshifting promoted by normal plus defective ribosomes.

References

1. Alani, *et al.*, Genetics 116:541-545 (1987).
2. Anderson, *et al.*, EMBO J. 17:1497-1506 (1998).
3. Balasundaram, *et al.*, Proc. Natl. Acad. Sci. USA 91:172-176 (1994).
- 5 4. Benard, *et al.*, Mol. Cell. Biol. 18:2688-2696 (1998).
5. Bishop, *et al.*, Annu. Rev. Biochem. 47:35-88 (1978).
6. Brierley, *et al.*, J. Gen. Virol. 76:1885-1892 (1995).
7. Brierley, *et al.*, Cell 57:537-547 (1989).
8. Brierley, J. Mol. Biol. 227:463-479 (1992).
- 10 9. Bruenn, *et al.*, Nucleic Acids Research 3:2427-436 (1976).
10. Christianson, *et al.*, 1992. Yeast 110:119-122 (1992).
11. Cui, *et al.*, Mol. Cell. Biol. 18:1506-1516 (1998).
12. Cui, *et al.*, EMBO J. 15:5726-5736 (1996).
13. Cui, *et al.*, Genes & Dev. 9:423-436 (1995).
- 15 14. Cui, *et al.*, Mol. Cell. Biol (1998).
15. Czaplinski, *et al.*, Genes & Dev. 12:1665-1667 (1998).
16. Dinman, *et al.*, Yeast 11:1115-1127 (1995).
17. Dinman, *et al.*, Proc. Natl. Acad. Sci. USA 88:174-178 (1991).
18. Dinman, *et al.*, RNA 3:870-881 (1997).
- 20 19. Dinman, *et al.*, Proc. Natl. Acad. Sci. USA 94:6606-6611 (1997).
20. Dinman, *et al.*, Trends in Biotech. 16:190-196 (1998).
21. Dinman, *et al.*, J. Virology 66:3669-3676 (1992).
22. Dinman, *et al.*, Genetics 136:75-86 (1994).
23. Dinman, *et al.*, Genetics 141:95-105 (1995).
- 25 24. Farabaugh, *et al.*, Microbiol. Rev. 60:103-134 (1996).
25. Fried, *et al.*, Proc. Natl. Acad. Sci. USA 75:4224-4228 (1978).
26. Fried, *et al.*, Proc. Natl. Acad. Sci. USA 78:238-242 (1981).
27. Gesteland, *et al.*, Annu. Rev. Biochem. 65:741-768 (1996).
28. Grant, *et al.*, Genetics 83:667-673 (1976).
- 30 29. Hsu, *et al.*, Molecular & Cellular Biology 13:4826-4835 (1993).
30. Jacks, *et al.*, Curr. Top. Microbiol. Immunol. 157:93-124 (1996).
31. Jacks, *et al.*, Cell 55:447-458 (1998).
32. Jimenez, *et al.*, Biochim. Biophys. Acta 383:427-434 (1975).

33. Johnson, *et al.*, Molecular & Cellular Biology 15:2719-2727 (1995).
34. Lee, *et al.*, Proc. Natl. Acad. Sci. USA 92:6587-6591 (1995).
35. Masison, *et al.*, Mol. Cell. Biol. 15:2763-2771 (1995).
36. Morikawa, *et al.*, Virology 186:389-397 (1992).
- 5 37. Muhlrad, *et al.*, Genes & Dev. 6:2100-2111 (1992).
38. Noller, *et al.*, J. Bacteriol. 175:5297-5300 (1993).
39. Noller, *et al.*, Annu. Rev. Biochem. 66:679-716 (1997).
40. Ohtake, *et al.*, Mol. Cell. Biol. 15:2772-2781 (1995).
41. Peltz, *et al.*, " Identification of the *cis*-acting sequences and *trans*-acting
10 factors involved in nonsense-mediated mRNA decay," p. 1-10. In Tuite, *et al.*, (eds.),
Protein synthesis and targeting in yeast. Springer-Verlag (1993).
42. Ridley, *et al.*, Molecular & Cellular Biology 4:761-770 (1984).
43. Ruiz, *et al.*, EMBO J. 17:575-589 (1998).
44. Ruiz, *et al.*, Proc. Natl. Acad. Sci. USA 95:8721-8726 (1998).
- 15 45. Schindler, *et al.*, Nature 248:535-536 (1974).
46. Schultz, *et al.*, J. Bacteriol. 155:8-14 (1983).
47. Sikorski, *et al.*, Genetics 122:19-27 (1989).
48. Somogyi, *et al.*, Mol. Cell. Biol. 13:6931-6940 (1993).
49. Stevens, *et al.*, J. Biol. Chem. 255:3080-3085 (1980).
- 20 50. Stevens, *et al.*, Archives of Biochemistry & Biophysics 252:339-347
(1987).
51. TenDam, *et al.*, Virus Genes 4:121-136 (1990).
52. Thiele, *et al.*, Virology 137:2031 (1984).
53. Tu, *et al.*, Proc. Natl. Acad. Sci. USA 89:8636-8640 (1992).
- 25 54. Turner, *et al.*, J. Virol. 72:1036-1042 (1998).
55. Weng, *et al.*, Mol. Cell. Biol. 16:5491-5506 (1996)
56. Weng, *et al.*, Mol. Cell. Biochem. 16:5477-5490 (1996).
57. Weng, *et al.*, RNA 4:205-214 (1998).
58. Wickner, *et al.*, Microbiol. Rev. 60:250-265 (1996).
- 30 59. Wickner, *et al.*, Genetics 76:423-432 (1974).
60. Wickner, *et al.*, Proc. Natl. Acad. Sci. USA 79:4706-4708 (1982).
61. Zhang, *et al.*, Nature 390:96-100 (1997).

Table 1. Yeast Strains used in this study

Strain	Genotype	Source
1906	<i>MATa leu2 mak8-1 K⁻ MKT⁺</i>	R. Wickner
5X47	<i>MATa/MATa his1/+ trp1/+ ura3/+ K⁻R⁻</i>	"
2373	<i>MATa ura3 ski4-1 mkt1 K⁺⁺</i>	"
2898	<i>MATa ura3 ade3 his(5,6) ski6-2 K⁺⁺</i>	"
2413	<i>MATa ura3 cyh2 ski7-2 K⁺⁺</i>	"
JD100	<i>MATa ura3-52 his3 trp1-δ1 K1⁺</i>	This study
JD973	<i>MATa ura3-SK1 LEU2::hisG TRP1::hisG lys2-SK1 ho::LYS2 ade3-210S</i>	"
Cross JD980	JD100 X JD973 with <i>RPL3::hisG</i> on one chromosome	"
JD980-10C	<i>MATa lys2 his3 ura3 LEU2::hisG trp1-δ1 RPL3::hisG + pRPL3 or pmak8-1.</i>	"
JD13	<i>MATa his3 leu2 PEP4::HIS3 NUC1::LEU2 ura3 K1⁺</i>	"
JD111	<i>MATa ura3-52 lys2-801 trp1-δ1 leu2⁻ his3⁻ K1⁺</i>	"
JD890	<i>MATa ura3-52 trp1 leu2Δ1 his3Δ300 pbrΔ1-6 can1⁻ pep4::HIS3 SKI1::LEU2 [L-AHN M₁] K⁺⁺</i>	"
JD2	<i>MATa ura3 trp1 ade8 ski2-2 K⁺⁺</i>	"

Strain	^a %-1 RFS	^a %+1 RFS	^b Killer phenotype
1906 (<i>mak8-1</i>)	5.18 ± 0.12%	4.12% ± 0.16%	-
980-10C +pRPL3	1.93 ± 0.18%	5.34% ± 0.18%	+
980-10C +pmak8-1	4.85 ± 0.12%	5.47% ± 0.11%	-

Table 2. Assays of programmed -1 ribosomal frameshifting and the killer phenotype in yeast cells harboring the wild-type *RPL3* gene or the *mak8-1* allele. ^a % -1 ribosomal frameshifting was calculated by multiplying the ratio of p-1/p0 Beta-galactosidase activities by 100%. Absolute error is shown. ^bKiller phenotype was determined as described in Materials and Methods.

EXAMPLE 3

Cloning of tobacco L3 genes

Applicants have conducted experiments in tobacco by introducing double gene constructs: wild-type L3 and wild-type PAP; Mak8-11 and wild-type PAP, and L3delta (encoding the 100 N-terminal amino acids of L3) and wild-type PAP. Expression of each coding sequence is driven by a separate CaMV 35S promoter. The transgenic plants show no phytotoxicity due to expression of high levels of wild-type PAP. The lack of phytotoxicity is particularly apparent when the plants are compared to other transgenic tobacco plants expressing wild-type PAP but not L3.

The L3 genes of tobacco (*Nicotiana tabacum* cv Samsun) have not been previously identified or characterized. We have isolated two full-length cDNA clones encoding two distinct L3 genes by screening a cDNA library constructed from tobacco leaves. The library was created in a phagemid vector using the ZAP Expression System by Stratagene. Screening of the cDNA library was followed according to the manufacturer's protocol.

The tobacco L3 genes were cloned by screening the lambda Zap library with the full-length cDNA of yeast L3 (*RPL3* gene). Even though yeast L3 is only 68% homologous to *Arabidopsis* L3, sufficient sequence similarity exists to use the yeast L3 to probe the tobacco library. This probe was incubated with the phagemid DNA transferred to nitrocellulose filters to allow hybridization. Positive matches were visualized by autoradiography and re-screened to confirm the hybridization. Positive pBK-CMV

phagemid vectors were excised from the ZAP Express vector and transferred to XL0LR host cells (Stratagene), which contain a stable kanamycin selection gene.

The pBK-CMV phagemid DNA was purified from these XL0LR cells and the tobacco gene insert was released by digestion with the EcoRI and XhoI restriction enzymes. The resulting insert was 1.4 kb, comparable in size to the *Arabidopsis* L3 genes. The insert was characterized by DNA sequence analysis. Sequencing resulted in the identification of two distinct and complete cDNAs of tobacco L3 genes (8d and 10d). Unlike yeast, which has a single L3 gene, both *Arabidopsis* and rice contain two L3 genes. A BLAST database sequence search showed greatest similarity between the L3 genes of tobacco and *Arabidopsis*. The L3 genes of tobacco are 80 % identical in nucleotide sequence. GCG analysis indicated that both L3 genes contain a complete open reading frame that translates a single protein of 389 amino acids (data not shown). This analysis was confirmed by *in vitro* transcription and translation of the two cDNAs in the TNT Coupled Reticulocyte Lysate System by Promega. The translation of either L3 genes produced a protein of approximately 44 kDa which was similar in molecular weight to yeast L3 at 43.5 kDa and the two *Arabidopsis* L3s, both at 44 kDa.

Construction of plant expression vectors: NT286 (tobacco L3-8d, sense) and NT292 (tobacco L3-8d, antisense), NT243 (yeast L3+PAP), NT244 (yeast mak8+PAP)

Tobacco L3 gene 8d was cloned into the plant expression vector pEL103 downstream of the CaMV35S promoter in sense orientation to generate NT286 and in antisense orientation to generate NT292.

The yeast L3 gene was cloned in sense orientation into the plant expression vector containing PAP to generate NT243 and mak8 was cloned in sense orientation into the plant expression vector containing PAP, to generate NT244. Expression of both L3 and mak8 genes was driven by the CaMV 35S promoter.

One of the two point mutations found in the yeast mak8 gene (P257S) was engineered into the tobacco L3 gene 8d in the vector NT315.

Transformation of tobacco plants with NT286, NT292, NT243, and NT244:
NT286, 292, 243, and 244 were transformed into tobacco, *Nicotiana tabacum* cv Samsun N and n via *Agrobacterium*-mediated transformation. ELISA assays were performed on the regenerants to select NPTII-positive transgenic plants using an assay kit manufactured by Agdia.

Analysis of transgenic tobacco plants (*N. tabacum* cv Samsun N), containing NT243 (L3+PAP)

Out of 12 plants regenerated (*N. tabacum* cv Samsun N), ten were found to be NPTII-positive. These plants were numbered as NT243-2, 4, 5, 6, 7, 8, 9, 10, 11 and 12. PCR results demonstrated that both PAP and L3 genes can be detected in NT243-2, 6, 7, 8, 9, 10, 11 and 12. Immunoblot analysis revealed that PAP was expressed at various levels in these transgenic plants, with NT243-7 and NT243-9 as the highest, followed by NT243-6 and NT243-8. These results were strikingly different from the results reported in Lodge, *et al.*, (1993). We observed a significant decrease in transformation frequencies with wild type PAP and generated only two transgenic lines with very low levels of expression. In contrast, we were able to generate 10 different transgenic lines when PAP was introduced together with yeast L3. Although the highest expressors NT243-7 and NT243-9 showed lesions on their leaves, the majority of these lines had normal phenotype. The observation that the other eight transgenic lines were free of mosaic symptoms suggests a possible interaction between wild type PAP and yeast L3, which can reduce or eliminate the cytotoxicity of PAP.

To determine whether transgenic tobacco plants containing NT243 were resistant to virus infection, 5 µg/ml tobacco mosaic virus (TMV) was inoculated onto two leaves (upper and lower) of NT243-2, 4, 6, and 8 lines. As shown in Table 3, these transgenic plants are highly resistant to TMV infection in terms of the local lesion numbers compared to wild type tobacco plants. These results suggest that the interaction between these two genes resulted in normal-looking plants and rendered the plants highly resistant to TMV infection.

Table 3. Susceptibility of transgenic tobacco plants to infection by 5 µg/ml TMV

Line	Lesion # on lower leaf	Lesion # on upper leaf
WT	31	18
NT243-2	0	0
NT243-4	0	0
NT243-6	0	2
NT243-8	4	1
NT244-1	20	8
NT244-2	15	3
NT286-5	9	8
NT286-6	8	6
NT292-2	29	7
NT292-3	7	5

Analysis of transgenic tobacco plants (*N. tabacum* cv Samsun N) containing NT244 (mak8+PAP)T

Three different transgenic tobacco plants (*N. tabacum* cv Samsun N) were generated. All three plants were phenotypically normal and indistinguishable from wild type tobacco plants. PCR analysis showed that both PAP and mak8 genes were present in these transgenic lines. Plants from lines NT244-1 and 2 showed lower numbers of local lesions, compared to the wild type plants (Table 3), indicating that they were resistant to TMV. However, the level of resistance was lower compared to NT243 (L3+PAP) plants.

Analysis of transgenic tobacco plants (*N. tabacum* cv Samsun n) containing NT243 and NT244

Eight different transgenic tobacco plants (*N. tabacum* cv Samsun n) were regenerated and confirmed to be transgenic by ELISA analysis for NT243. Similarly, eight different transgenic tobacco plants (*N. tabacum* cv Samsun n) were regenerated and confirmed to be transgenic by ELISA analysis for NT244. These plants were phenotypically indistinguishable from wild type tobacco plants, except NT243-2, which was slightly mosaic. Surprisingly however, PAP was expressed at relatively high levels in every plant. Yeast L3 expression was also detected in transgenic lines NT243-1, 2, 4, and 6.

Analysis of transgenic tobacco plants containing NT286 (tobacco L3-8d, sense) and NT292 (tobacco L3-8d, antisense)

Several transgenic tobacco plants were generated with NT286, containing the tobacco 8d gene in sense orientation and with NT292, containing the tobacco 8d gene in antisense orientation, as determined by ELISA. Two different transgenic lines NT286-5 and 6, containing the tobacco L3 gene in sense orientation and one transgenic line NT292-3, containing the tobacco L3 gene in antisense orientation showed resistance to TMV (Table 3).

Isolation of new L3 mutants:

The purpose of these experiments has been to identify new variants (alleles) of the yeast gene encoding ribosomal protein L3 (RPL3) that mimic the mak8-1 allele. The mak8-1 allele is incapable of maintaining an endogenous yeast virus called M1, and it is also resistant to pokeweed antiviral protein (PAP). Certain genetic conditions had to be established to allow for the identification of new rpl3 mutants. First, we had to accumulate a collection of mutant versions of the RPL3 gene. To do this, a plasmid-based clone harboring the wild-type RPL3 gene was passaged through *E. coli* XL-1 Red cells

(commercially available from Strategene Inc., La Jolla CA). The genetic makeup of these cells allows for the accumulation of multiple mutations in DNA sequences. The mixed population of plasmids harvested from the *E. coli* XL-1 Red cells constituted the collection or "library" of mutant *rpl3* genes. Second, since the RPL3 gene is essential for life, we had to set up genetic conditions that would enable us to switch the mutant *rpl3* genes for the wild-type RPL3 genes in cells. To do this, we constructed an RPL3 gene knockout yeast strain (*rpl3*-delta). Here, the RPL3 gene was deleted from the yeast chromosome, and a plasmid borne copy of RPL3 provides the gene product. The genetics were set up so that we could start with the *rpl3*-delta strain harboring the wild-type RPL3 gene on a plasmid, introduce another plasmid harboring mutant *rpl3* (from the library), and then force the cells to lose the wild-type RPL3 copy. This was done by putting the wild-type gene on a URA3 plasmid, the library on a TRP1 plasmid, and selecting for growth on medium containing 5-fluorootic acid, which serves as a URA3 poison. Cells that had lost the wild-type gene were then assayed for their ability to maintain the M1 virus by means of the standard yeast killer virus assay. To date, over 40 mutants have been identified. The DNA sequence of five of these has been determined. Interestingly, they are all identical: they harbor a single mutation at nucleotide residue 845 in the RPL3 gene that switches a cytosine for a thymidine base. This results in a change at amino acid residue 282, changing the wild-type isoleucine to a threonine. Interestingly, this mutation is close by the original *mak8-1* mutations at amino acid residues 255 and 257.

INDUSTRIAL APPLICABILITY

The present invention has applicability in the field of agricultural biotechnology, and more particularly to the production of seed that produces transgenic plants exhibiting increased resistance to viruses and/or fungi that infect plants and tend to decrease yield. The trans-nucleic acid that imparts these properties to the plants is substantially non-toxic.

The present invention also has medical applications, particularly for conditions amenable to treatment with single-chain RIPs, particularly PAP, that bind endogenous L3 proteins but which exhibit a toxic effect on non-diseased cells.

The present invention further has industrial applications in the production of recombinant RIPs for pharmaceutical and therapeutic uses. All patent and non-patent publications cited in this specification are herein incorporated by reference to the same

extent as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

We claim:

1. A transgenic plant containing an exogenous nucleic acid encoding an L3 protein.
2. The transgenic plant of claim 1 wherein said nucleic acid is derived from yeast.
3. The transgenic plant of claim 1 wherein said nucleic acid is derived from a higher
5 plant or an animal.
4. The transgenic plant of claim 1 wherein said nucleic acid is heterologous to said plant.
5. The transgenic plant of claim 1 wherein said nucleic acid is homologous to said plant.
- 10 6. The transgenic plant of claim 1 wherein the L3 protein encoded by said nucleic acid is a wild-type L3 protein.
7. The transgenic plant of claim 1 wherein the L3 protein encoded by said nucleic acid is a spontaneously occurring mutant of L3.
8. The transgenic plant of claim 7 wherein said spontaneously occurring mutant of L3
15 is tcm1.
9. The transgenic plant of claim 1 wherein the L3 protein encoded by said nucleic acid is a non-naturally occurring mutant of L3.
10. The transgenic plant of claim 9 wherein said non-naturally occurring mutant of L3 is rpl3-I282T.
- 20 11. The transgenic plant of claim 9 wherein said non-naturally occurring mutant of L3 is Mak8 (W255C, P257S).
12. The transgenic plant of claim 1 wherein said nucleic acid is a first exogenous nucleic acid and wherein said plant further comprises a second exogenous nucleic acid encoding a single chain ribosome inhibitory protein (RIP) that binds an endogenous
25 L3 protein.
13. The transgenic plant of claim 12 wherein the RIP encoded by said second nucleic acid is a PAP protein, PAP-v or a PAP II protein.
14. The transgenic plant of claim 1 that is a monocot plant.
15. The transgenic plant of claim 1 that is a dicot plant.
- 30 16. The transgenic plant of claim 1 that is a cereal crop plant.
17. A plant cell transformed with the nucleic acid of claim 1.
18. A protoplast transformed with the nucleic acid of claim 1.
19. Seed derived from the transgenic plant of claim 1.

20. A method of increasing resistance to viruses and/or fungi in a plant, comprising introducing the exogenous nucleic acid of claim 1 into the plant whereby said exogenous nucleic acid is expressed, wherein expression of said nucleic acid in said plant results in increased resistance to viruses and/or fungi relative to a wild-type plant.
21. A method of reducing toxicity of a single chain ribosome inhibitory protein (RIP) contained in a plant, comprising introducing the first and second exogenous nucleic acids of claim 12 into the plant thereby preparing a first transgenic plant, whereby said first and second nucleic acids are expressed in said first transgenic plant, wherein expression of said first nucleic acid in said transgenic plant results in reduced toxicity to the RIP produced by expression of said second nucleic acid relative to a second transgenic plant expressing said second exogenous nucleic acid but not said first exogenous nucleic acid.
22. A method of preparing a plant having increased resistance to viruses and/or fungi, comprising introducing the exogenous nucleic acid of claim 1 into a plant cell or protoplast to produce a transformed plant cell or protoplast, and regenerating a whole, transgenic plant from said transformed cell or protoplast, whereby said exogenous nucleic acid is expressed in said transgenic plant, wherein expression of said exogenous nucleic acid in said plant results in increased resistance to viruses and/or fungi relative to a wild-type plant.
23. A method of reducing toxicity to single chain ribosome inhibitory proteins (RIPs) in a plant, comprising introducing the first and second exogenous nucleic acids of claim 12 into a plant cell or protoplast to produce a transformed plant cell or protoplast, and regenerating a first transgenic plant from said transformed cell or protoplast, whereby said first and second nucleic acids are expressed in said first transgenic plant, wherein expression of said first nucleic acid in said first transgenic plant results in reduced toxicity to the RIP produced by expression of said second nucleic acid relative to a second transgenic plant expressing said second exogenous nucleic acid but not said first exogenous nucleic acid.
24. A method of reducing toxicity associated with single-chain ribosome inhibitory proteins (RIPs), comprising co-administering to a cell a single-chain RIP that binds an endogenous ribosome of the cell and an L3 protein.

25. The method of claim 24 wherein said cell contains a first exogenous nucleic acid encoding the RIP and a second exogenous nucleic acid encoding the L3 protein.
26. The method of claim 25 wherein said cell is a bacterium.
27. The method of claim 24 wherein said L3 protein is a non-naturally occurring mutant
5 of L3 protein that (a) substantially fails to bind single chain ribosome inhibitory proteins that bind endogenous L3 proteins, (b) is unable to maintain M1 killer virus, (c) promotes altered programmed ribosomal frameshift efficiency, (d) exhibits resistance to peptidyltransferase inhibitors and combinations of any of (a)-(d).
28. A nucleic acid encoding a non-naturally occurring mutant of L3 protein that (a)
10 substantially fails to bind single chain ribosome inhibitory proteins that bind endogenous L3 proteins, (b) is unable to maintain M1 killer virus, (c) promotes altered programmed ribosomal frameshift efficiency, (d) exhibits resistance to peptidyltransferase inhibitors and combinations of any of (a)-(d).
29. A cell transformed with the nucleic acid of claim 28.
- 15 30. The cell of claim 29 which is a bacterium or a yeast cell.
31. The cell of claim 29 which is the bacterium *E. coli*.
32. A non-naturally occurring mutant of L3 protein that (a) substantially fails to bind single chain ribosome inhibitory proteins that bind endogenous L3 proteins, (b) is substantially unable to maintain M1 killer virus, (c) promotes altered programmed
20 ribosomal frameshift efficiency, (d) exhibits resistance of peptidyltransferase inhibitors and combinations of any of (a)-(d).
33. The L3 mutant of claim 32 which is rp13-I282T
34. The L3 mutant of claim 32 which is Mak8 (W255C, P257S).
35. A composition comprising the non-naturally occurring mutant of L3 of claim 32 and
25 a carrier.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/31312

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12N 15/01, 5/04, 15/82; A01H 1/06, 4/00, 5/00, 5/10

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.1, 69.9, 410, 418, 419, 421, 440, 463, 468; 800/278, 279, 280, 288, 295, 301, 320

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WEST
DIALOG

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,646,026 A (WALSH et al) 08 July 1997 (08/02/97), column 2, line 55 through column 20, line 58, see entire document.	1,3,5-7,9, 14-20 and 22
Y	US 5,248,606 A (WALSH et al) 28 September 1994 (28/09/93), column 2, line 50 through column 8, line 61, see entire document.	1,3-7,14-20 and 22
Y	US 5,196,510 A (RODWELL et al) 23 March 1993 (23/03/93), column 4, line 5 through column 5, line 22, see entire document.	20 and 22
Y	LINTHORST et al. Constitutive Expression of Pathogenesis- Related Proteins PR-1, GRP, and PR-S in Tobacco Has No Effect on Virus Infection. The Plant Cell. March 1989, Vol. 1, pages 285-291, see entire document.	1-11, 14-20 and 22

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"B" earlier document published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"A" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

23 MARCH 2000


Date of mailing of the international search report

14 APR 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

VICTER MUHAMMAD 

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/31312

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	KIM et al. Two Evolutionarily Divergent Genes Encode a Cytoplasmic Ribosomal Protein of <i>Arabidopsis thaliana</i> . Gene. 1990, Vol. 93, pages 177-182, see entire document.	1-11, 14-20 and 22

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/31312

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-11, 14-20 and 22

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/31312

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

+35/69.1, 69.9, +10, +18, +19, +21, +40, +63, +68; 800/278, 279, 280, 288, 295, 301, 320

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-11, 14-20 and 22, drawn to a transgenic plant, plant cell, seeds and protoplast and a method of increasing resistance.

Group II, claims 12-13, 21 and 23, drawn to a transgenic plant comprising second gene encoding RIP protein and method of use.

Group III, claims 24-27, drawn to a method of reducing toxicity via direct applications of RIP protein to a plant.

Group IV, claims 28-31, drawn to a nucleic acid encoding a non-naturally occurring mutant of L3 protein and bacterial cells transformed therewith.

Group V, claims 32-35, drawn to a non-naturally occurring mutant of L3 protein and composition thereof.

The inventions listed as Groups I-V do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The inventions are not linked by a single special feature which constitutes an advance over the prior art, since Kim et al, Linthorst et al, Rodwell et al, Walsh et al (US 5,646,026), and Walsh et al (US 5,248,606), cited in the Search Report, were found to anticipate or suggest the claimed invention. Furthermore, each invention involves physiologically and biochemically divergent products and processes not required by any other, such as a transgenic plant and its method of use, a transgenic plant encoding an RIP protein and its method of use, a method of reducing toxicity via topical protein application, a nucleic acid encoding a non-naturally occurring mutant and a non-naturally occurring mutant of L3 protein.

In the absence of any response from applicant, this Authority will establish the International Preliminary Examination report based on the main invention. The claims drawn to the main invention are as follows:

Claims: 1-11, 14-20, and 22.